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ABSTRACT 
A decade a? er iden? ? ca? on of the human kinome, only a frac? on of the kinome has been 
systema? cally studied. This clearly illustrates the lack of knowledge regarding the func? ons 
and cellular e? ects that these proteins have in the establishment of cellular phenotypes. 
Surprisingly, recent evidence suggests that approximately 23% of all kinase genes were 
es? mated to func? on as cancer genes.  
The overall aim of this thesis project was to shed light on the mechanisms controlling 
protein kinase ac? vity and func? on, par? cularly in human cancers. A global and comprehensive 
interactomics analysis of the signaling networks of the evolu? onarily conserved CMGC-protein 
kinase family, consis? ng of cyclin-dependent kinases (CDK), mitogen-ac? vated protein kinases 
(MAPK), glycogen synthase kinase-3 (GSK3) and CDC-like kinases (CLK) was performed. From 
this physical and func? onal interac? on analysis, hundreds of novel interac? ons, kinase-
substrate rela? onships and previously unknown links to human diseases, such as cancer 
were iden? ? ed (I). The unprecedented sensi? vity and speci? city of this approach was also 
illustrated, and highlighted, for example, by the puri? ca? on and iden? ? ca? on of the complete 
transla? onal co-ac? vator complex (the Mediator complex) with two of the CMGC kinases 
(CDK8 and CDK19). At the same ? me, the Mediator complex was iden? ? ed mutated in benign 
uterine human tumors (uterine leiomyomas). To further deepen the understanding of the role 
of CDK8 and CDK19 kinases in controlling human disease pathways, we studied the func? onal 
role of two MED12 muta? ons in uterine leiomyoma and prostate cancer (II-III). Based on 
these studies, MED12 was found essen? al for the kinase ac? vity of CDK8 in the context of 
the Mediator kinase module. Furthermore, disrup? on of the Mediator kinase module subunit 
interac? ons was shown as a common mechanism contribu? ng to the forma? on of uterine 
leiomyoma. The MED12 mutants in leiomyoma and prostate cancer were shown func? onally 
di? erent. Finally, a novel MED12 nuclear localiza? on signal was iden? ? ed, and its importance 
in the correct nuclear localiza? on of MED12 and subsequent proper assembly and func? on of 
the Mediator kinase module was experimentally proven (IV). The described results from the 
mul? disciplinary studies (I-IV) clarify the cellular roles of CMGC kinases and Mediator subunits, 
facilita? ng the design of targeted future therapies/therapeu? cs against human diseases.   
 

1I  REVIEW OF THE LITERATURE 
1.   PROTEIN KINASES
At any given ? me in any given eukaryote cell, mul? ple types of molecular networks are 
concurrently ac? ve. An important feature of these networks is the mul? ple reversible reac? ons 
of protein phosphoryla? on (catalyzed by protein kinases) and dephosphoryla? on (catalyzed by 
protein phosphatases) (Figure 1). Protein kinases form an essen? al part of signal transduc? on in 
eukaryo? c cells by phosphoryla? ng speci? c protein substrates. For plethora of proteins, changes 
in phosphoryla? on status are ? ghtly linked to their ac? vity, cellular loca? on and/or associa? on 
with other proteins. Thus, the change in phosphoryla? on status a? ects a mul? tude of cellular 
processes like metabolism, transcrip? on, cell cycle progression, cytoskeletal rearrangement 
and cell mo? lity, apoptosis and, di? eren? a? on. Altera? ons in protein phosphoryla? on have 
been func? onally linked to a variety of human diseases.  
Figure 1: Phosphoryla? on and dephosphoryla? on are mediated by kinases and phosphatases. 
Protein kinases transfer the high-energy phosphate group from ATP to serine, threonine or tyrosine 
residues of substrate proteins. The work of protein kinases is undone by protein phosphatases that 
remove the phosphate by hydrolysis. 
Simply put, phosphoryla? on is the transfer of a phosphate group of an ATP molecule to a target 
protein’s serine (S), threonine (T) or tyrosine (Y) residues by protein kinases. Based on their 
selec? vity of the target amino acid, protein kinases are divided into serine/threonine (Ser-/
Thr-speci? c), tyrosine (tyrosine-speci? c) and dual-speci? city protein kinases that are serine/
threonine kinases, but are also able to phosphorylate on tyrosine. Most of cellular processes 
are controlled by serine/threonine protein kinases. The rates of cellular phosphoryla? on events 
di? er drama? cally, giving ra? os of 1800(Ser):200(Thr):1(Tyr) (Mann et al., 2002). 
1.1  Structure of protein kinases 
A common feature for all eukaryo? c protein kinases is the existence of a cataly? c core. This 
highly conserved twin-lobed kinase core consists of N- and C-terminal lobes with an ATP binding 
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2cle?  between the lobes (Figure 2). The N-lobe has ? ve ?-strands and an ?-helix, whereas 
C-lobe contains mostly helices (Taylor and Kornev, 2011). The N-lobe ?-strands serve as binding 
surfaces for ATP, and the ?-helix is a regulatory unit important for kinase ac? va? on also 
connec? ng N- and C-lobes. The C-lobe contains the substrate binding groove and the ac? va? on 
segment consis? ng of cataly? c loop, DFG mo? f, ac? va? on loop, P+1 loop, and APE region 
(Kannan and Neuwald, 2004) (Figure 2). The cataly? c and regulatory func? ons of the ac? va? on 
segment are needed for the correct transfer of the phosphate residue to the substrate. 
Mammalian protein kinases, themselves, are under ? ght regula? on, and DFG mo? f 
regulated phosphoryla? on of the ac? va? on loop acts as the switch for ac? va? on and 
deac? va? on (Taylor and Kornev, 2011). Indeed, ac? va? on loop phosphoryla? on is the most 
common mechanism to regulate kinase ac? vity (Nolen et al., 2004). Upon phosphoryla? on 
most protein kinases are in their ac? ve ‘on’ state, and dephosphorylated in the basal ‘o? ’ state. 
It is, therefore, not surprising that the three-dimensional structure of ac? va? on segment in 
di? erent ac? ve protein kinases is highly similar, but in contrast inac? ve conforma? ons vary 
greatly allowing kinase speci? c ac? va? on mechanisms and, thus, high speci? city (Taylor and 
Kornev, 2011). Ac? va? on of protein kinases can also depend on the priming phosphoryla? on of 
the substrate (Kannan and Neuwald, 2004). 
Figure 2: Structure of kinase core and schema? c illustra? on of the ac? va? on segment. A) Structure 
of CDK2 kinase core. N- and C-lobes are indicated with grey and green background, respec? vely. 
Ac? va? on segment is visualized with yellow. B) Nomenclature of the ac? va? on segment extending 
from the conserved DFG mo? f ? ll the conserved APE in the P+1 loop. Aspartate (D) in the DFG 
mo? f is a cataly? c residue responsible of chela? ng magnesium (Mg2+), which further posi? ons 
ATP phosphates during phosphotransfer. Ac? va? on loop contains the primary phosphoryla? on 
site determining the conforma? on of the loop and the ac? vity of the kinase, and which is the site 
of regulatory phosphoryla? on or interac? on with kinase ac? vity modulators. P+1 loop provides 
a docking site to the neighboring residues to the residues to be phosphorylated in the pep? de 
substrate. APE region stabilizes the whole segment. (Modi? ed from Nolen et al., 2004) 
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1.2  CMGC kinases - an evolu? onarily conserved kinase family 
consis? ng of CDKs, MAPKs, GSK3, and CDKL kinases
In 2002, Manning and co-workers iden? ? ed 518 protein kinases in the human genome, 
forming one of the largest families of genes in eukaryotes cons? tu? ng approximately 2% of 
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Figure 3: Human protein kinase family tree, and CMGC family conserva? on among species. The 
kinase tree shows the sequence similarity between protein kinases based on their kinase domain. 
ACG, containing PKA, PKG, PKC families; CAMK, calcium/calmodulin-dependent protein kinase; CK1, 
casein kinase-1; STE, homologs of yeast Sterile 7/11/20 kinases; TK, tyrosine kinase; TKL, tyrosine 
kinase-like. Illustra? on reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com). 
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all human genes (Manning et al., 2002). This collec? on of over ? ve hundred protein kinases, 
forming the human ‘kinome’, were further grouped into seven major families based on the 
structural similari? es in their cataly? c domain (Figure 3). According to the similari? es in their 
kinase domains cyclin-dependent kinases (CDKs), mitogen-ac? vated protein kinases (MAPKs), 
glycogen synthase kinase-3 (GSK3s), CDC-like kinases (CLKs) and their related kinase families, 
form a kinase family termed CMGC (Manning et al., 2002). The CMGC family is highly conserved, 
implying that their func? ons are highly important for the existence of various species ranging 
from nematode to human (Figure 3).
CMGC kinases, as with other protein kinases have a conserved kinase core, but they also 
share a dis? nc? ve CMGC-insert segment, which is lacking in other protein kinases (Kannan 
and Neuwald, 2004). The CMGC-insert, located in the C-lobe, is associated with binding 
to co-proteins that par? cipate in kinase func? on (Pawson and Nash, 2003) (Figure 4). This 
domain does not present high homology among the family members, thus enabling substrate 
speci? city. CMGC kinases are mainly regulated either through tyrosine phosphoryla? on in the 
ac? va? on loop (Johnson et al., 1996), or through the pre-phosphoryla? on of the substrate, 
preparing it for sequen? al recogni? on and phosphoryla? on by these kinases (ter Haar et al., 
2001). Another common func? onal feature is the preference to phosphorylate substrates 
having proline in P+1 posi? on. 
Figure 4. The CMGC-speci? c structural features P+1 and CMGC insert. (Modi? ed from Oruganty 
and Kannan, 2012). 
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5In total the CMGC family has 62 (uniprot.org, Varjosalo et al., 2008) members, which can 
be further classi? ed into eight (Manning et al., 2002) subfamilies, where CDKs and MAPKs form 
the two most studied and largest families with 21 and 14 members, respec? vely (Malumbres 
et al., 2009). Other families are DYRKs (dual-speci? city tyrosine (Y)-phosphoryla? on-regulated 
kinases; 10), CLKs (4), RCKs (tyrosine kinase gene v-ros cross-hybridizing kinase; 3), CDKLs 
(cyclin dependent kinase like; 5), GSK3s (2), and SRPKs (SR-speci? c protein kinase; 3) (Figure 3). 
Most of the CMGC kinases can be assigned to par? cular biological func? ons including 
control of the cell cycle (CDKs), cell fate decisions (MAPKs), regula? on of mul? ple signaling 
pathways (GSKs), and RNA splicing (CLKs). The individual subfamilies and their speci? c features 
will be described in detail below. 
1.3  CMGC kinase subfamilies
1.3.1  CDK (cyclin dependent kinase)
CDKs or cyclin dependent kinases form a family of 21 cons? tu? vely expressed serine/threonine 
kinases that regulate cell cycle, transcrip? on, mRNA processing, and di? eren? a? on of cells 
(Malumbres, 2014). CDKs, as their name indicates, are dependent on cyclins - proteins whose 
levels constantly ? uctuate in a ? ghtly coordinated manner during the cell cycle (Figure 5). In 
the CDK/cyclin complexes, CDKs func? on as the cataly? c subunits, whereas cyclins are the 
regulatory subunits that are needed for CDKs to present enzyma? c ac? vity. Indeed, the main 
mechanism to regulate the enzyma? c ac? vity of CDKs is the produc? on and degrada? on rate of 
cyclins. The CDK ac? va? on loop contains the residues for both cyclin and subsequent ATP binding 
and as with most eukaryo? c protein kinases, CDKs are also controlled by phosphoryla? on 
of the ac? va? on segment.  Phosphoryla? on has either inhibitory e? ects via interference on 
ATP binding at the cataly? c cle?  or ac? va? ng e? ects when the phosphoryla? on site acts as a 
substrate of CDK-ac? va? ng kinases including other CDKs. Ac? va? ng phosphoryla? on improves 
substrate binding by promo? ng full kinase ac? vity (Je? rey et al., 1995; Russo et al., 1996). 
CDK ac? vity is downregulated by two families of small proteins that func? on as CDK 
inhibitors during the cell cycle. A family of cyclin-dependent kinase inhibitors, INK4 proteins, 
acts during G1, speci? cally inhibi? ng the binding of CDK4/CDK6 with cyclin D (Harper and 
Brooks, 2005; Malumbres, 2014), whereas the broader spectrum inhibitors of the Cip/Kip 
family inhibit the ac? vity of the CDK/cyclin -complexes throughout the cell cycle (Harper and 
Brooks, 2005; Malumbres, 2014).  
Based on evolu? onary clustering CDKs form kinase subfamilies that regulate separate 
en? ? es within the cell. CDKs 1-4, and 6 are mainly involved in cell cycle regula? on, whereas 
CDKs 7-9, 11-13, and 19 have established roles in transcrip? on (Malumbres, 2014). Other CDKs 
have variable roles that will be discussed later.
Cell cycle regula? on by CDKs (CDK1, -2, -3, -4 and -6)
Most living organism are unicellular, but others like humans consist of millions of cells. During 
development of these mul? cellular organisms mul? ple rounds of cell growth and division have 
to take place, and this process con? nues throughout the life of an individual. This elegant, 
? ghtly regulated universal process of cell growth and division, where a cell duplicates its 
contents and divides into two is known as the cell cycle.   
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6In a normal situa? on, the cell cycle is under ? ght regula? on at each state through the 
ac? va? on or deac? va? on of a mul? tude of proteins. The mammalian cell cycle has ? ve phases: 
G0 (res? ng state), G1 and G2 (RNA and protein synthesis), S (DNA replica? on) and M (mitosis 
and comple? on of cell division), where mul? ple checkpoints ensure normal progression from 
one phase to another. Each checkpoint has its own speci? c cyclin/CDK complexes controlling 
the cell cycle progression (Figure 5). Brie? y, cyclin C/CDK3 complex assists cells in G0-G1 
transi? on (Ren & Rollins, 2004; uniprot.org). Cyclin D/CDK4(CDK6) ini? ate the transfer through 
G1 through phosphoryla? on of the re? noblastoma protein that leads to transcrip? on of 
genes needed for DNA synthesis and further progression of the cell cycle. Cyclin E/CDK2 is 
a gatekeeper in the G1/S transi? on and is responsible for the hyper-phosphoryla? on of the 
re? noblastoma protein. During S phase, cyclin A accumulates, and the ac? vity of cyclin A/CDK2 
is essen? al for S phase termina? on via phosphoryla? on of transcrip? on factor E2F1. Cyclin A/
CDK1 and cyclin B/CDK1 are important for progression through G2 and M phase (Harper and 
Brooks, 2005; Malumbres, 2014). CDK7 can also in? uence cell cycle by ac? ng as CDK-ac? va? ng 
kinase, phosphoryla? ng for example CDK1 and CDK2 (Fisher, 2012). 
Figure 5: The cell cycle and ? uctua? on of cyclin levels during the cell cycle progression. The cell 
cycle is divided into ? ve phases: G0 (senescence), G1 (cell decides to grow or to enter G0), S (DNA 
replica? on), G2 (cells prepare for entry into mitosis), and M (mitosis, cell division). The CDK/cyclin 
complexes important for di? erent phases are drawn on the inner rim of the cell cycle, and the 
? uctua? ng levels of cyclins on the outer rim. The ? uctua? ons in cyclin levels are ? ghtly linked to the 
di? erent phases of cell cycle. However, the levels of cyclin D are strongly in? uenced by extracellular 
signals from growth factors. 
To study the func? onal roles of individual cell cycle related CDKs in vivo mul? ple knockout mice 
have been made (Figure 6). The analyses of knockout animals ablated of one or more of the 
cell cycle related CDKs, CDK1 (Santamaria et al., 2007), CDK2 (Ortega et al., 2003; Berthet et 
al., 2003), CDK4 (Rane et al., 1999; Tsutsui et al., 1999), and CDK6 (Malumbres et al., 2004) 
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7have shown that only CDK1 is essen? al for embryonic cell division leading to early embryonic 
lethality. CDK2, 4, and 6 are mainly needed for the development of dis? nct cell types and the 
knockout animals develop normally into adulthood (Barrière et al., 2007). CDK4/CDK6 double 
knockout mutant embryos die in utero (Malumbres et al., 2004). 
Figure 6: Transgenic CDK-mice.  Genotypes of the various knockout mice used to study the role of 
cell cycle -linked CDKs are indicated. The arrows and stop signs indicate the embryonic development 
stage to which the corresponding CDK knockout animal develops. (Modi? ed from Malumbres and 
Barbacid, 2009)
Transcrip? on ini? a? on, elonga? on and termina? on regula? on by CDKs (‘transcrip? onal 
CDKs’: CDK7, -8, -9 -11, -12, -13 and -19)
To u? lize the informa? on that is stored in the cellular DNA, cells need to copy this gene? c 
informa? on to an RNA nucleo? de sequence in a ? ghtly regulated process termed transcrip? on. 
Transcrip? on on all protein-coding genes is dependent on RNA polymerase II (RNA pol II). RNA 
pol II has a C-terminal domain (CTD) composed of polypep? de repeats that are phosphorylated 
in a gene speci? c manner to regulate the ac? vity of RNA pol II. The ? rst step in transcrip? on 
is the recruitment of RNA pol II to the promoter of the transcribed gene. This task, among 
others, is performed by transcrip? on preini? a? on complex (PIC), composed of several general 
transcrip? on factors (TFIIA, TFIIB, TFIID, TFIIE, IFIIF, TFIIH), the Mediator complex, and RNA pol 
II itself (Figure 7). 
The TFIIH has mul? ple subunits, one of which is the subcomplex composed of CDK7, cyclin 
H and MAT1. The TFIIH complex is important at the transcrip? on start site as it unwinds the 
DNA, posi? ons it correctly in the RNA pol II ac? ve site and phosphorylates a serine (primarily 
Ser-5, but can also be Ser-7) at the CTD of RNA pol II to ini? ate RNA produc? on. When the 
transcript has gained a certain threshold length, RNA pol II sheds most of the ? rst transcrip? on 
factors, and new factors are recruited on site. During elonga? on one of these newly recruited 
factors is the CDK9/cyclin T containing posi? ve transcrip? on elonga? on factor, pTEFb.  The 
CDK9 subunit phosphorylates another serine (Ser-2) in the CTD of RNA pol II. CDK12 interacts 
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8with cyclin K and has been shown to phosphorylate the same serine-2 in the CTD. CDK12, 
CDK11 and CDK13 also act in alterna? ve RNA splicing (uniprot.org; Even et al., 2006; Loyer et 
al., 2008). The last step of transcrip? on is termina? on releasing both the RNA pol II from the 
template DNA and mRNA from the transcrip? onal complex. 
The presence of CDK8 and CDK19 containing Mediator complex is also necessary for 
RNA pol II phosphoryla? on, although the main task of Mediator is to transfer gene-speci? c 
regulatory signals from mul? ple transcrip? on factors to RNA pol II (Allen, Taatjes, 2015). 
To date, knockout animal models of transcrip? onal CDKs are available only for CDK7 
(Ganuza et al., 2012), CDK8 (Westerling et al., 2007), CDK11 (Li et al., 2004), and CDK12 (Juan et 
al., 2016). All of these knockouts are embryonic lethal during early development.
Other CDKs (CDK5, -10, -14, -15, -16, -17, -18, and -20)
CDK5 is expressed in post-mito? c cells like neurons (Liu, W. et al., 2017). The presence of CDK5 
is essen? al for developing brain (Ohshima et al., 1996), and later in adult brain it is involved in 
mul? ple neuronal processes including learning and memory, survival, synap? c plas? city, and 
pain signaling (Shah and Lahiri, 2014). It is considered as a poten? al target in the treatment 
of neurodegenera? ve diseases such as Alzheimer’s and Parkinson’s disease (Shah and Lahiri, 
2014). In brain, CDK5 is ac? vated by interac? on with the non-cyclins CDK5R1 (p35) or CDK5R2 
(p39). Cyclins D1, D3, and E have been reported to form a complex with CDK5 (Shah and Lahiri, 
2014), and in 2009 (Brinkkoe? er et al., 2009), cyclin I was iden? ? ed as a new CDK5 ac? vator. 
Recently cyclin I-like (CCNI2), a homolog of cyclin I, was shown to ac? vate CDK5, a? ect its 
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Figure 7: Illustra? on of the transcrip? on preini? a? on complex. Transcrip? on ac? vators bind to the 
ac? va? on domains (enhancers) and, thus, turn ‘on’ the gene. As indicated in the illustra? on, these 
enhancer regions (indicated with orange) might reside rela? vely distant to the start of the gene 
(lilac). Transcrip? on factors assemble at the promoter region of the DNA. The Mediator complex 
conveys the signals from TFs to RNA pol II, and transcrip? on begins at the ini? a? on site (grey). 
(Modi? ed from Vojnic et al., 2011)
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cellular localiza? on and have a role in cell cycle progression and cell prolifera? on (Liu, C. et al., 
2017).  
Only recently the func? onal role and ac? va? ng cyclin of CDK10 was detected (Guen et al., 
2013). Previously, silencing of CDK10 was linked to ETS2-driven increased expression of c-RAF 
leading to MAPK pathway ac? va? on, and loss of estrogen responsiveness of breast cancer cells 
causing tamoxifen resistance in certain breast tumors (Iorns et al., 2008). The study of Guen et 
al. (2013) indeed showed that cyclin M interacts with CDK10 and this complex phosphorylates 
ETS2 transcrip? on factor and posi? vely controls ETS2 degrada? on by the proteasome. 
CDK14 to CDK18 belong to the PFTAIRE and PCTAIRE kinase subfamilies (HUGO Gene 
Nomenculature Commi? ee, genenames.org). CDK14 and CDK16 are ac? vated at the plasma 
membrane by cyclin Y and par? cipate in mul? tude of signaling cascades such as the Wnt 
pathway (Jiang et al., 2009; Shehata et al., 2012). This pathway is known to control transcrip? on 
and its regulators are also important during mitosis. Noteworthy, cyclin Y expression has also 
been shown to peak during the G2-M phase of the cell cycle. Both of these observa? ons 
suggest these enzymes playing a role in cell division (Malumbres, 2014). CDK15, CDK17 and 
CDK18 are the least studied CDKs. CDK15 has been shown to phosphorylate survivin and lead to 
reduc? on in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induced apoptosis 
(Park et al., 2014). Elevated phosphoryla? on of CDK17 and CDK18 was recently iden? ? ed in 
neuroblastoma cell line expressing amyloid precursor protein (APP) and also validated in brain 
samples from Alzheimer’s disease pa? ents (Chaput et al., 2016). This ? nding iden? ? es novel 
targets for APP and raises further ques? ons about the role of CDKs in neurodegenera? ve 
diseases. 
CDK20 has a role in ciliary length control and knockdown of this protein promoted cilia 
forma? on and cilia stability in the absence of kinase ac? vity (Yang, Y. et al., 2013).
1.3.2  MAPK (mitogen-ac? vated protein kinase)
This family of serine/threonine kinases has 14 members that can be divided into atypical and 
conven? onal kinases. The la? er can be further subdivided into four subfamilies: 1) extracellular 
signal-regulated kinases (ERKs), 2) c-Jun amino-terminal kinases (JNKs), 3) p38 MAPKs and 4) 
ERK5. All of these enzymes are characterized by a system where three kinases act in a row 
to phosphorylate the downstream kinase (Figure 8). For ERKs the ac? vators are MEK1 and 
MEK2, for JNKs- MKK4 and MKK7, for p38- MKK3 and MKK6, and for ERK5- MEK5. MAPK are 
highly conserved, respond to extracellular signaling clues and regulate many important cellular 
processes like prolifera? on, di? eren? a? on, and stress responses together with transcrip? onal 
control of CDKs in organisms ranging from yeast to human. Enormous amount of research has 
focused on MAPKs during the last decades, from their substrates and func? ons, to their role in 
health and disease. 
10
Figure 8: MAPK, MAPKK, MAPKKK. Each of the MAP kinases (MAPK) is ac? vated by an upstream 
MAPK kinase (MAPKK), which is ac? vated by MAPKK kinase (MAPKKK). The s? mulus is speci? c 
to each MAPK subfamily. For ERK1/2, mitogenic s? mulus leads to phosphoryla? on of Raf 
(MAPKKK) that further phosphorylates MEK1/2 (MAPKK) that ? nally phosphorylates ERK1/2. A? er 
ac? va? on by phosphoryla? on the MAPK translocates into the nucleus, and ac? vates TCF family 
transcrip? on factors. Most target genes for ERK1/2 are genes a? ec? ng prolifera? on, cell division 
and di? eren? a? on. For JNKs MKK4 and MKK7 act as MAPKK responding to stress signals, similar 
to p38 and MAPKKs MKK3 and MKK6. ERK5 responds to morphogenic clues via MEK5 promoted 
phosphoryla? on.
ERK (extracellular signal-regulated kinase)
ERKs respond to di? erent s? muli ranging from growth factors to insulin to cytokines and 
carcinogens (Johnson and Lapadat, 2002; Cargnello and Roux, 2011). They are components 
of the cell surface receptor (receptor tyrosine kinase)/RasGTP/Raf/MEK/ERK -signaling 
cascade. Components of this signaling cascade have been shown to be essen? al for proper 
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cell prolifera? on. ERKs func? on both in the cytoplasm to promote cell prolifera? on (G1 to S 
phase transi? on), and in the nucleus to phosphorylate and ac? vate mul? tude of transcrip? on 
factors (TFs) (Cargnello and Roux, 2011; Buro? o et al., 2014). Upon TF ac? va? on c-Jun is 
expressed, and stabilized by direct phosphoryla? on by ERK1/2 (Murphy et al., 2002) allowing 
associa? on with c-Fos and subsequent forma? on of AP-1 complex. AP-1 is essen? al for cyclin 
D1 expression, which interacts with CDKs to drive G1 to S transi? on.
JNK (c-Jun N-terminal kinase)
All three JNKs are highly homologous (>85%), but have dis? nct ? ssue distribu? on. JNK1 and 
2 are ubiquitously expressed, while the expression of JNK3 is mainly limited to the brain. In 
contrast to ERKs, JNKs are mostly ac? vated by stress signals including oxida? ve stress, radia? on, 
and DNA-damaging agents. JNKs are mainly localized to the cytoplasm, but their iden? ? ed 
substrates are mostly TFs including c-Jun, p53, STAT3 and c-Myc. The phosphoryla? on of 
c-Jun leads to AP-1 complex forma? on and thus transcrip? on of cyclin D1 promo? ng cell cycle 
progression, akin to ERK1/2 (Sabapathy et al., 2004). To date, only a few cytoplasmic interac? on 
partners of JNKs have been iden? ? ed (Bogoyevitch et al., 2010; Cargnello and Roux, 2011).
p38
The four members of p38 subfamily (?, ?, ?, ?) respond to various environmental stress s? muli 
and cytokines like interleukin-1 and tumor necrosis factor ? (TNF). Interes? ngly, p38 both 
regulates the produc? on of cytokines and responds to them. Other targets of p38 regula? on 
are TFs and other protein kinases. Based on the observa? ons of p38 ac? va? on, it has a role in 
in? amma? on, cell cycle regula? on and apoptosis (Cuadrado and Nebreda, 2010; Cargnello and 
Roux, 2011). 
ERK5 (BMK1 or big MAP kinase 1)
ERK5 has a kinase domain that is similar to ERK1/2, having 51% similarity with ERK2. ERK5 is 
essen? al during normal embryogenesis (Regan et al., 2002). An upstream ac? vator of ERK5 is 
MEK5, whose expression is elevated in metasta? c prostate cancer (Mehta et al., 2003). Similar 
to ERK1/2 and JNK, ERK5 also promotes cyclin D1 expression and cell cycle progression (Mulloy 
et al., 2003).  
1.3.3  GSK3 (glycogen synthase kinase-3)
Glycogen synthase kinase-3 is a conserved, widely expressed serine/threonine kinase. A unique 
feature of GSK3 is its high ac? vity in res? ng cells. Humans have two forms of GSK3s: GSK3? and 
-?, which have 85% overall sequence homology (Woodge? , 1990). The kinase domain of these 
kinases is highly homologous (98%), whereas the N- and C-terminal domains di? er (Woodge? , 
1990). GSK3? and -? are func? onally di? erent, as homozygous GSK3? mice are embryonic 
lethal but GSK3? mice are viable (Hoe? ich et al., 2000; MacAulay et al., 2007). Di? erent from 
CDK and MAPK families described above, the ac? vity of GSK’s is regulated on mul? ple levels 
and ways ranging from phosphoryla? on by other kinases to autophosphoryla? on, and to need 
for priming phosphoryla? on of the target substrate by another kinase (Frame and Cohen, 2001; 
Cole et al., 2004; McCubrey et al., 2016). In most cases, phosphoryla? on of serine residues has 
been shown to inhibit GSK3’s kinase ac? vity, while tyrosine phosphoryla? on leads to increased 
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kinase ac? vity (Medina and Wandosell, 2011). GSK3 (mainly GSK3?) has been extensive 
studied and have a known func? on in variety of signaling pathways ranging from Wnt, Notch 
and Hedgehog (prolifera? on) to growth factors a? ec? ng di? eren? a? on/survival. It is implicated 
to have mul? ple roles in many human pathological condi? ons ranging from neurodegenera? ve 
diseases to diabetes and several types of cancers (Cormier & Woodge? , 2017; McCubrey et al., 
2016). 
As GSK3 is a crucial component of the canonical Wnt signaling pathway, which is important 
during normal development and o? en gone awry in cancers. The following is a short summary 
of the main events during Wnt-?-catenin signaling. A central component of this pathway is the 
destruc? on complex that regulates the cytoplasmic ?-catenin levels. The destruc? on complex 
is composed of tumor suppressors Axin and adenomatosis polyposis coli (APC) together with 
casein kinase-1? (CK1?) and GSK3 (Niehrs, 2012). In the absence of Wnt-ligand, ?-catenin is 
assembled into this complex, phosphorylated by CK1 and GSK3 labelling it for proteasomal 
degrada? on, thus preven? ng the transcrip? on of ?-catenin dependent genes. Upon Wnt 
binding to its receptor Frizzled, the destruc? on complex is not able to phosphorylate and 
ubiqui? nate ?-catenin, which then translocates to the nucleus where it forms complexes 
with transcrip? on factors and promotes transcrip? on (Figure 9). Phosphoryla? on by GSK3 is 
essen? al also for targe? ng mul? ple other proteins for proteasomal degrada? on. (Kaidanovich-
Beilin and Woodge? , 2011; Cormier and Woodge? , 2017)
Figure 9: Simpli? ed pathway of Wnt-?-catenin GSK3. In the absence of Wnt ligand, the cellular 
?-catenin levels are kept low.  The phosphoryla? on of ?-catenin by the destruc? on complex enables 
recogni? on and ubiqui? na? on by E3 ubiqui? n ligase ?-TrCP (?-transducin repeats containing 
protein) further targe? ng ?-catenin for proteasomal degrada? on (Wnt OFF state, le? ). Upon ligand 
binding to Frizzled and its co-receptor LRP (lipoprotein receptor-related protein), the destruc? on 
complex translocates to the plasma membrane. The binding of Axin to LRP is catalyzed by LRP 
phosphoryla? on by other destruc? on complex components (GSK3 or CK1). Cytoplasmic levels of 
?-catenin accumulate leading to its translocaliza? on into the nucleus and subsequent induc? on of 
TCF family transcrip? on factors.
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1.3.4  CLK (cdc2-like kinase) and other less-studied kinases
The four Cdc2-like kinases or CLKs are dual speci? city kinases that autophosphorylate at 
tyrosines, but speci? cally phosphorylate serine/threonine residues on their substrates (Nayler 
et al., 1997). CLKs localize to cytoplasm and nucleus, where they phosphorylate the arginine 
and serine (RS)-rich domains on serine/arginine (SR) splicing factor proteins thus controlling 
their nuclear distribu? on (Bullock et al., 2009). SR splicing factor proteins are extensively 
phosphorylated by mul? ple kinases, and the correct phosphoryla? on status has been shown 
essen? al for the ac? vity of SR proteins (Prasad et al., 1999). These protein are indispensable 
for the alterna? ve mRNA splicing - a fundamental process responsible of the produc? on of the 
complex human proteome during normal development.
In a recent study, CLKs were iden? ? ed upstream of Aurora B ac? ng as novel components 
in the ? nal steps of cytokinesis, the division of cytoplasm into two cells (Petsalaki and Zachos, 
2016). But as Petsalaki and Zachos concluded, our understanding, to date, of the cellular 
func? ons of CLKs is rather limited (Petsalaki and Zachos, 2016). 
SRPK (SR-speci? c protein kinase)
Serine-arginine protein kinases speci? cally phosphorylate serine residues in serine/arginine/
arginine-serine dipep? des. They are mainly localized in the cytoplasm, where these 
cons? tu? vely ac? ve kinases regiospeci? cally phosphorylate SR splicing factors on mul? ple 
serines inducing the transloca? on of these factors into nucleus, where they are further 
phosphorylated by CLKs (Giannakouros et al., 2011; Ghosh and Adams, 2011). The change in 
the cellular localiza? on of the SR proteins is essen? al to phosphoryla? on by CLKs (Bullock et al., 
2009). As men? oned above, SR protein phosphoryla? on is necessary for correct mRNA splicing 
and matura? on. 
Over 100 hundred SR-domain containing proteins have been iden? ? ed in the human 
genome (Calarco et al., 2009), indica? ng mul? ple open ques? ons of the func? onal roles of 
SRPKs in mammalian cells. SRPK1 expression is elevated in breast, colonic, and pancrea? c 
cancers (Hayes et al., 2007) as well as acute T-cell leukemia (Hishizawa et al., 2005). SPRK2 has 
a speci? c role in phosphoryla? ng apoptosis promo? ng protein ACIN1 and increasing cyclin A1 
expression on leukemia cells (Jang et al., 2008).
RCK (tyrosine kinase gene v-ros cross-hybridizing kinase)
The RCK serine/threonine-protein kinase family consists of three kinases MAK, ICK and MOK, 
whose func? ons are poorly understood. Structurally RCK family resembles both MAPKs and 
CDKs (Manning et al., 2002). MAK and ICK autophosphorylate on a tyrosine residue, but need 
a second phosphoryla? on on their MAPK-like mo? f in their ac? va? on loop by an upstream 
kinase for full enzyma? c ac? vity (Fu, Z. et al., 2005; Wang and Kung, 2011; Miyata et al., 1999). 
Di? erent from MAPK, the ac? va? ng kinase for MAK and ICK is cell cycle related kinase (CCRK), 
but for MOK it remains unknown (Wang and Kung, 2011; Fu, Z. et al., 2006).
MAK (male germ cell-associated kinase) is mainly expressed in the tes? cular germs cells 
during spermatogenesis and in the re? na in the back of the eye (Omori et al., 2010; Tucker et 
al., 2011). In the re? na MAK localizes to connec? ng cilium in photoreceptor cells, nega? vely 
regulates the length of their cilia and is essen? al for the survival of these cells (Omori et al., 
2010). Not surprisingly, MAK muta? ons are associated with re? ni? s pigmentosa, an illness of 
photoreceptor degenera? on in the re? na (Ozgul et al., 2011; Tucker et al., 2011). 
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ICK (intes? nal cell kinase) is highly conserved, cons? tu? vely and widely expressed. 
Similarly to MAK, it nega? vely regulates ciliary length and, in addi? on, is iden? ? ed as an 
important component of sonic hedgehog signaling (Moon et al., 2014). These two factors seem 
to be the underlying cause of human ECO syndrome, a mul? -organ illness a? ec? ng endocrine, 
cerebral and skeletal systems, caused by a missense muta? on in ICK gene (Lahiry et al., 2009). 
The cellular func? on of the third RCK, MOK (MAPK/MAK/MRK-overlapping kinase), 
is largely unknown. To date, only the expression of MOK in mouse wildtype and cancerous 
intes? nal cells has been analyzed by western blo?  ng, showing downregula? on of MOK in 
adenomas (Chen, T. et al., 2013). This interes? ng observa? on suggests that MOK might have a 
role in intes? nal cancer development, but further studies are needed. 
CDKL (cyclin dependent kinase like)
This family of ? ve members of serine/threonine kinases with homology to MAPK and CDK 
families is hitherto rather uncharacterized. Studies focused on CDKL5, a ubiquitous protein 
mainly expressed in the brain, testes and thymus (Lin et al., 2005). CDKL5 muta? ons have been 
iden? ? ed in a severe neurodevelopmental disorder, the Re?  syndrome (Weaving et al., 2004; 
Tao et al., 2004). In postnatal brain, CDKL5 has similar expression pa? ern as metyl-CpG-binding 
protein (MECP2), whom CDKL5 directly interacts with and mediates its phosphoryla? on (Mari 
et al., 2005). MECP2 is also frequently found mutated in the Re?  syndrome (Van den Veyver 
and Zoghbi, 2001), whether CDKL5 and MECP2 are components of a common cellular pathway 
remains an open ques? on. 
1.3.5  DYRK (Dual-speci? city tyrosine (Y)-phosphoryla? on-regulated kinase)
DYRK is a rela? vely large mammalian dual-speci? city protein kinase family, that based on 
homology analysis consists of three subfamilies having in total 10 members: DYRK (DYRK1A-B, 
2-4), HIPK (homeodomain-interac? ng protein kinase 1-4), and PRP4 (pre-mRNA processing 
protein 4 kinase). 
DYRK 1-4 
The DYRK subfamily members are autophosphorylated on tyrosine within the ac? va? on loop 
during their transla? on resul? ng in a cons? tu? vely ac? ve mature protein (Lochhead et al., 
2005). Autophosphoryla? on of this conserved tyrosine is essen? al for achieving full kinase 
ac? vity (Himpel et al., 2001). As DYRKs are not subject to the classical MAPK-like regula? on by 
an upstream protein kinase, other regulatory mechanisms have been proposed. All of these 
subfamily members experience changes in their cytoplasmic versus nuclear localiza? on, which 
are speculated to limit substrate accessibility and, thus, regulate DYRK1-4 (Aranda et al., 2011). 
Other regulatory mechanisms for DYRKs might be altera? ons in gene expression and protein 
abundance or interac? ons with regulatory proteins. Thus far DYRKs are not shown to undergo 
regula? on by reversible phosphoryla? on or dephosphoryla? on (Aranda et al., 2011). 
The major func? on of mammalian DYRKs is the regula? on of the cell cycle. Both DYRK1A 
and DYRK1B can be classi? ed as survival and di? eren? a? on promo? ng factors. DYRK1A has 
been shown to control the length of G1 phase via regula? ng cyclin D1 levels and to promote 
the transi? on between quiescence and di? eren? a? on (Chen, J. Y. et al., 2013). DYRK1B is ac? ve 
in quiescent cells preven? ng entry into G1 by stabilizing CDK inhibitors and destabilizing cyclin 
D (Zou et al., 2004; Deng et al., 2004). In apoptosis DYRK1A, DYRK3, and DYRK2 have opposite 
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roles, as DYRK1A and DYRK3 phosphorylate either directly pro-apopto? c proteins or their 
inhibitors leading to inhibi? on of apopto? c ac? vity (Seifert et al., 2008; Guo et al., 2010), while 
the phosphoryla? on of p53 by DYRK2 (or HIPK2) promotes apoptosis (Taira et al., 2007). 
Another common character of the DYRKs is their ac? on as priming serine/threonine kinases 
for consequent phosphoryla? on by GSK3 thus targe? ng proteins for proteasomal degrada? on 
(Aranda et al., 2011). To date DYRK family members have been iden? ? ed as priming kinases 
for oncoproteins c-Jun and c-Myc in addi? on to transcrip? on factor GLI2 (Taira et al., 2007; 
Varjosalo et al., 2008).  
Although the func? ons of the fourth member of this subfamily, DYRK4, are ambiguous, 
based on the molecular roles of other DYRKs, one can conclude that the members of this 
subfamily are involved in cell survival, cell di? eren? a? on, gene transcrip? on and transla? on 
(Aranda et al., 2011).
Clinical relevance of DYRK subfamily
The most studied member is DYRK1A – mostly due to the gene localiza? on in chromosome 
21, which is triplicated in Down syndrome. Individuals a? ected with Down syndrome have 
an elevated risk of developing Alzheimer’s disease. Due to chromosomal trisomy leading to 
elevated DYRK1A expression on transcrip? onal and protein level, DYRK1A is thought to func? on 
in the pathogenesis of neurodegenera? on in this pa? ent popula? on (Park et al., 2009). The 
hyperphosphoryla? on of tau, a hallmark protein of Alzheimer’s disease, by DYRK1A observed 
in Down syndrome pa? ents, poten? ally also contributes to neurodegenera? on in normal 
popula? on. 
HIPK (homeodomain-interac? ng protein kinase)
HIPKs, like DYRKs, are autophosphorylated to reach full kinase ac? vity (van der Laden et al., 
2015). HIPK1 to 3 are highly homologous, whereas the later iden? ? ed fourth member, HIPK4, 
is only related to others in its cataly? c domain (Arai et al., 2007). Most of the knowledge of 
HIPKs comes from HIPK2, which is known to act in cell cycle, apoptosis and responses to DNA 
damage mostly via interac? ons with TFs. The ac? vity of HIPK2 itself is orchestrated by mul? ple 
post-transla? onal modi? ca? ons and caspase-mediated cleavage (van der Laden et al., 2015). 
Due to structural similarity, HIPK1 is thought to have a similar role in cells as HIPK2 (Aikawa 
et al., 2006). A recent study iden? ? ed HIPK2 as a facilitator of Dishevelled phosphoryla? on, 
maintaining cells responsive to Wnt ligand s? mula? on (Shimizu et al., 2014). The molecular 
func? ons of both HIPK3 and, especially, HIPK4 are s? ll rather uncharacterized.   
PRP4 (pre-mRNA processing protein 4 kinase) 
A subfamily of ubiquitously expressed kinases that regulate pre-mRNA splicing and acts as a 
spindle assembly checkpoint protein (Kojima et al., 2001; Montembault et al., 2007). Recently 
the kinase domain of PRP4 was iden? ? ed essen? al for pancrea? c and colorectal tumor cell 
viability (Gao et al., 2013).   
1.3.6  Protein kinase therapeu? cs – kinase inhibitors 
The protein kinase domain is among the most commonly encountered domain in known cancer 
genes (Futreal et al., 2004). As described earlier, most of the kinase pathways are involved 
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in cri? cal cellular processes like prolifera? on, apoptosis, or survival, and o? en, abnormal 
phosphoryla? on is either the cause or consequence in cancer (Cohen, 2002). Therefore, 
protein kinases are among the most studied druggable targets in pharmacological research 
to date (Knight et al., 2010; Abbassi et al., 2015). In human cancers, kinases are o? en found 
overexpressed or overac? ve, due to vast array of gene? c and epigene? c events including point 
muta? ons, chromosomal gene ampli? ca? ons (copy number altera? ons), and chromosomal 
transloca? ons giving rise to gene fusions (Gross et al., 2015).
Oncogenic rela? ons of CMGC family members 
Combined data from six recent studies iden? ? ed a total of 1100 genes that drive cancer 
development. From this list, an enrichment of protein kinases was observed (91 kinases were 
present) (Fleuren et al., 2016). Six of them (6/91; ~7%) belonged to CMGC kinase family (Fleuren 
et al., 2016) involving family members of CDK, MAPK and DYRK; namely CDK4, CDK6, CDK12, 
MAPK1 (Erk2), MAPK8 (JNK1)), and DYRK1A. Expectedly, the altera? ons observed in these genes 
were either point muta? ons or copy number changes (Fleuren et al., 2016). Other studies have 
also iden? ? ed ampli? ed CDK12 expression in breast cancers and inac? vated in ovarian cancers 
(Kauraniemi et al., 2001 and 2003; Joshi et al., 2014). In addi? on, over-expression of CDK7 
together with MAT1 and cyclin H was detected in >900 estrogen receptor posi? ve (ER+) breast 
cancer samples (Patel et al., 2016). DYRK1B overexpression has been observed in pancrea? c 
and ovarian cancer (Friedman, 2007), and in osteosarcomas and rhabdomyosarcomas (Yang 
et al., 2010; Mercer et al., 2006). Interes? ngly, the deple? on of DYRK1B drove pancrea? c and 
ovarian cancer cells to apoptosis (Deng, X. et al., 2006; Hu, et al., 2013).
CMGC kinase inhibitors
Based on the common structural features of protein kinases, presented in detail earlier in this 
work, the majority of protein kinase inhibitors target the ATP-binding site in the ac? va? on 
segment, thus compe? ng with ATP. The second-genera? on inhibitors target protein kinase in a 
speci? c conforma? on and are thought to be more speci? c. However, there are highly selec? ve 
and broad range inhibitors within both genera? ons of kinase inhibitors (Treiber and Shah, 
2013). 
Several pan-CDK inhibitors have been studied in di? erent phases in clinical trials, and 
currently mul? ple ongoing trials are announced to assess the e? ects of mul? target CDK 
inhibitors, seliciclic, dinaciclib, and AT7519, in di? erent cancers either as single therapeu? c 
agent or in combina? on with other agents (clinicaltrials.gov). Unfortunately, a common 
shortcoming of kinase inhibitors is the rela? vely low percentage of pa? ents presen? ng 
sa? sfactory response (Knight et al., 2010). The best clinical outcome is usually reached with a 
polypharmacological approach, using drug combina? ons either within a single kinase pathway 
or targe? ng parallel kinase pathways in preselected pa? ent popula? ons (Knight et al., 2010; 
Gross et al., 2015).
The ? rst US Food and Drug Administra? on (FDA) approved CMGC family kinase inhibitor 
was Palbociclib. It is a selec? ve CDK4 and CDK6 inhibitor, approved for the treatment of ER 
posi? ve and human epidermal growth factor receptor-2 nega? ve (ER+/HER2-) advanced breast 
cancer (Beaver et al., 2015). Currently there are over 50 clinical trials listed for Palbociclib 
(clinicaltrials.gov), studying, among others, the e? ects in acute leukemias, neuroendocrine 
tumors, and metasta? c breast cancer. Some of these studies combine Palbociclib with other 
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kinase inhibitors or already established pharmaceu? cals (for example tamoxifen), or have 
targeted pa? ent popula? ons with certain predic? ve biomarkers. 
Abemaciclib, another speci? c CDK4 and CDK6 inhibitor, received a breakthrough therapy 
status from FDA in October 2015, and a successful phase III combina? on trial in pa? ents with 
hormone receptor posi? ve (HR+), HER2- advanced breast cancer was published in March 2017 
(h? ps://investor.lilly.com/releasedetail.cfm?releaseid=1017952). 
The third CDK4 and CDK6 speci? c inhibitor, Kisqali® (ribociclib), received FDA breakthrough 
therapy designa? on in 2016, and has been approved by FDA in March 2017 as a ? rst-line 
treatment for HR+/HER2- advanced or metasta? c breast cancer in combina? on with aromatase 
inhibitor (h? ps://www.novar? s.com/news/media-releases/novar? s-kisqalir-ribociclib-lee011-
receives-fda-approval-? rst-line-treatment). 
Currently, there are many ongoing clinical trials assessing p38 MAPK inhibitors in 
in? ammatory diseases, and ERK1/2 (MAPK1) inhibitor in advanced cancers, administered 
either alone or in combina? on with other pharmaceu? cal agents (clinicaltrials.gov).
A plethora of GSK3 inhibitors have been published and studied in clinical trials for the 
treatment of cancer or Alzheimer’s disease (Pandey and DeGrado, 2016). The ? rst GSK3 
inhibitor was lithium chloride (LiCl), which has been used in the treatment of bipolar disorder 
since 1950s. The main focus of the clinical studies has been in the treatment of Alzheimer’s 
disease. The neuroprotec? ve mechanism of GSK3 inhibitors is the reduc? on of ?-amyloid 
produc? on and tau hyperphosphoryla? on (Kramer et al., 2011). However, the results of the 
studies have been controversial, and none of the inhibitors have made it into clinical use 
(Pandey and DeGrado, 2016). 
A polyphenolic green tea ? avonol, epigallocatechin-3-gallate (EGCG), is DYRK1A inhibitor 
that was shown to normalize DYRK1A ac? vity in Down syndrome pa? ents in a pilot-study 
reversing cogni? ve de? cits (De la Torre et al., 2014). Inhibi? on of DYRK1A is an enchan? ng 
therapeu? c approach for the treatment of cogni? ve impairment in Down syndrome together 
with inhibi? ng tau hyperphosphoryla? on in Alzheimer’s disease (Abbassi et al., 2015). DYRK-
family inhibitors have also been shown e? ec? ve in vitro in reducing prolifera? on and inducing 
apoptosis either as single agents or as dual-inhibitors targe? ng CKL1 (Abbassi et al., 2015). At 
the moment several clinical studies are listed to evaluate the e? ect of EGCG in cancer pa? ents 
(clinicaltrials.gov).    
The oncogenic poten? al and inhibitors of CDK8 are discussed later in the context of the 
Mediator kinase module.
2. THE MEDIATOR COMPLEX
The mammalian Mediator is a large protein complex (~2 MDa) that has been described as 
the central hub and master regulator of transcrip? on ac? ng on mul? ple levels ranging from 
epigene? c regula? on, transcrip? on elonga? on and termina? on to mRNA processing and 
enhancer forma? on (Yin and Wang, 2014; Clark et al., 2015). As brie? y men? oned earlier, the 
main func? on of the Mediator is to transmit the informa? on of general transcrip? on factors 
to RNA pol II. In mammals, the Mediator complex has 30 subunits that can exist in mul? ple 
composi? ons. The core Mediator complex consists of 26 subunits forming the head, middle, 
and tail, and addi? onal subunits forming the kinase module (Figure 10). The Mediator kinase 
module is composed of 4 subunits: CDK8/CDK19, MED13 (or MED13L), MED12 (or MED12L) 
and cyclin C (Clark et al., 2015; Allen and Taatjes, 2015; Yin and Wang, 2014). MED13 serves as 
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a direct link between CDK8 and other Mediator components (Knuesel et al., 2009a; Tsai et al., 
2013). 
Transcrip? on factors bind to their speci? c subunits within the Mediator, thus permi?  ng 
the simultaneous binding of mul? ple TFs. On the other hand, the absence of certain Mediator 
subunit only disrupts the downstream e? ects of certain TFs, and not all, as the binding partners 
for other TFs are s? ll present (Allen and Taatjes, 2015). 
The gigan? c size of the Mediator complex o? ers an enormous pla? orm for protein-protein 
interac? ons, at the same ? me causing problems in func? onal analysis (Allen and Taatjes, 2015). 
The Mediator was ? rst discovered in yeast Saccharomyces cerevisiae (Kelleher 3rd et al., 1990; 
Flanagan et al., 1991), and has since been found across eukaryotes with conserved, basic 
func? ons in TF and RNA pol II binding. Interes? ng observa? on is, however, that the subunit 
composi? on and sequences of the Mediator subunits are not highly conserved from yeast to 
man, allowing ? ne-tuning of the processes they control (Allen and Taatjes, 2015). 
2.1  Mediator kinase module: CDK8/CDK19, MED12, MED13, and cyclin C
CDK8 and CDK19 were previously classi? ed in this work as transcrip? onal CDKs because of their 
associa? on with the Mediator complex. More speci? cally, CDK8 and CDK19 form the kinase 
domain together with MED12, MED13, and cyclin C. CDK8 binds to cyclin C, but reaches full 
kinase ac? vity only in CDK8-cyclinC-MED12 complex (Knuesel et al., 2009b). MED12 also serves 
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Figure 10: Illustra? on of the Mediator complex components. The Mediator subunits forming the 
middle, head, tail and kinase module are listed on the right. (Modi? ed from Tsai et al., 2014.) 
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as a central hub within the kinase module, connec? ng CDK8/cyclin C and MED13. MED13 
further connects the kinase module with the Mediator core (Tsai et al., 2013). Informa? on 
from TF binding Mediator tail and kinase domains is conveyed through the Mediator middle 
and head to RNA pol II (Clark et al., 2015). 
During transcrip? on, the Mediator tail and kinase modules serve as binding sites for 
gene speci? c transcrip? on factors working in context-dependent transcrip? onal repression 
or ac? va? on. Ac? va? on of signal transduc? on a? er TF phosphoryla? on by CDK8 has been 
observed, for example, in the interferon pathway, where STAT1 is a target for CDK8 (Bancerek 
et al., 2013). Another target of CDK8, E2F1, usually promotes ?-catenin degrada? on. Upon 
phosphoryla? on by CDK8, the ac? vity of E2F1 is repressed leading to increased ?-catenin levels, 
o? en observed in colon cancer (Morris et al., 2008). Intres? ngly, CDK8 has been iden? ? ed 
as a colorectal cancer oncoprotein (Firestein et al., 2008), and as a coac? vator of p53 tumor 
suppressor driven protein expression (Donner et al., 2007). 
Only small frac? on of cellular CDK8 is associated with the Mediator kinase module, and 
most likely there are other yet uncharacterized roles for CDK8 (Knuesel et al., 2009b). Although 
the kinase domain is now known to be essen? al for transcrip? on, the full details of the physical 
and func? onal interac? ons with core Mediator and RNA pol II remain unclear. 
2.1.1  Kinase module and cancer
In addi? on to having a plethora of func? onal roles during transcrip? on, as described above, 
the Mediator complex, and especially its kinase module, have been linked to development of 
mul? ple di? erent cancers (Clark et al., 2015). Figure 11 presents a summary of cancer types, 
where known muta? ons or other altera? ons in the kinase module components have been 
reported.
Figure 11: Oncogenic altera? ons in kinase module subunits (table based on the data on Clark et al., 
2015). 
An underlying common factor for tumorigenesis seems to be altered CDK8 kinase ac? vity 
(Clark et al., 2015). The dysfunc? on of the kinase module can result either from the gain of 
CDK8 kinase ac? vity, as observed in colorectal cancer, melanoma, pancrea? c, breast and 
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gastric cancer, or from CDK8 loss of func? on, iden? ? ed in uterine leiomyomas, T-cell acute 
lymphoblas? c leukemias (T-ALL) and endometrial cancers (Clark et al., 2015). The changes in 
kinase ac? vity can be due to muta? ons in CDK8 itself or happen through muta? ons in the other 
kinase module components, especially cyclin C or MED12. A phase I clinical study is currently 
recrui? ng pa? ents to assess BCD115, a CDK8/CDK19 inhibitor, in combina? on therapy in ER+/
HER- advanced breast cancer (clinicaltrials.gov). 
MED12 in uterine leiomyoma and prostate cancer
In 2011, a study was conducted to ? nd out high-frequency gene? c altera? ons in benign, 
common uterine tumors, uterine leiomyomas (Makinen et al., 2011) (Figure 12). 70% of these 
tumors carried a muta? on in exon 2 of MED12 gene. Almost 50% of studied leiomyomas 
displayed a missense muta? on in codon 44, with all possible nucleo? de subs? tu? ons. All 
of the muta? ons were predicted to result in an in-frame transcript with the most frequent 
muta? on reported as G44D (20.9%; Makinen et al., 2011). To further characterize the role 
of the Mediator kinase module in uterine leiomyomas, 70 MED12 muta? on-nega? ve uterine 
leiomyomas were screened for muta? ons in other kinase module components CDK8/CDK19, 
Cyclin C or MED13. Interes? ngly, none of these tumors displayed muta? ons in the other kinase 
module components, further valida? ng the tumorigenic role of MED12 muta? ons in uterine 
leiomyomas (Makinen et al., 2014). 
A? er the iden? ? ca? on of G44 as a muta? onal hotspot in uterine leiomyoma (Makinen et 
al., 2011), another MED12 gene muta? on L1224F a? ec? ng exon 26 in 5 out of 152 pa? ents was 
iden? ? ed in prostate cancer (Barbieri et al., 2012) (Figure 12). The prostate cancer speci? c area 
of MED12 muta? on is rather distant from the leiomyoma hotspot, thus presen? ng an open 
ques? on of whether the tumorigenic impact of these two muta? ons is similar or di? erent. The 
func? onal roles of these muta? ons need further studies. 
Figure 12. Schema? c illustra? on of the human MED12 showing the loca? on of the observed 
G44D, and L1224F muta? ons. Di? erent domains of MED12 are also indicated.  
 
3.  ‘OMICS’ METHODS TO STUDY KINASE BIOLOGY
Most of the studies regarding kinase interac? ons have focused on a single kinase and its 
func? on or dysfunc? on in a disease. Addi? onally, the names of the CDK kinases were uni? ed 
in 2009 (Malumbres et al., 2009), and that might have contributed to the slowness of studies 
of some these kinases. It is, a? er all, rather di?  cult to assign a kinase to this interes? ng family 
when the name is very di? erent, such as PFTK1 or CRKRS.  
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3.1  Protein-protein interac? ons
The ? rst high-throughput screenings of protein-protein interac? ons were performed using 
the yeast two-hybrid technique (Uetz et al., 2000). This method allows the iden? ? ca? on of 
binary interac? ons, thus assigning proteins to a biological context. Also human protein-protein 
interac? ons were ? rst studied in the yeast two-hybrid system as an important intermediate 
step towards a more systema? c and comprehensive analysis of human interactome (Rual et 
al., 2005). The next development in interactomics was the detailed characteriza? on of yeast 
protein complexes u? lizing a?  nity puri? ca? on coupled to mass spectrometry (AP-MS) (Krogan 
et al., 2006; Gavin et al., 2006). In 2009, Gla? er and co-workers (Gla? er et al., 2009) presented 
a sensi? ve, reproducible, high-throughput AP-MS work? ow for human cells. The general 
work? ow of an AP-MS experiment has three steps: 1) expression of the epitope-tagged bait 
protein, 2) single or double-step a?  nity puri? ca? on of the protein complexes, and 3) analysis of 
the complex components with liquid chromatography coupled to a mass spectrometer (Figure 
13). Several great advantages of this system are the use of Gateway®-compa? ble human 
Orfeome (Rual et al., 2004) collec? ons, genera? on of isogenic cell lines, inducible expression 
of bait proteins at near physiological levels, high yield and reproducibility a?  nity puri? ca? on 
together with direct, “gel free” analysis with LC-MS (Gla? er et al., 2009). Later, this approach 
was also shown to be robust and highly reproducible between laboratories (Varjosalo et al., 
2013a).  
Figure 13: An overview of the AP-MS work? ow. The isogenic, inducible HEK293 cell lines expressing 
Twin-Strep and hemagglu? nin -tagged baits are generated. The tagged protein with its binding 
partners is single-step a?  nity puri? ed from cell lysates u? lizing Strep-tac? n beads. The eluted 
proteins are trypsin digested and the resul? ng pep? des analyzed by LC-MS/MS. 
3.1.1  BioID proximity labeling
Proteins are not sta? c components of cells forming only binary interac? ons, but can also form 
indirect interac? ons within a protein complex or with nearby proteins (Roux et al., 2012). The 
BioID method for proximity labeling of interac? ng proteins is based on the ability of a modi? ed 
bio? n ligase (BirA*) to covalently a? ach a bio? n on the neighboring proteins lysine residues 
upon bio? n supplementa? on in the growth media (Roux et al., 2012). Work? ow for BioID 
sample analysis resembles AP-MS: the protein-of-interest (bait) is tagged with the BirA*, a?  nity 
puri? ed with streptavidin beads and analyzed with LC-MS (Figure 14). Endogenous bio? nyla? on 
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in mammalian cells is mainly limited to carboxylases, thus providing a rather speci? c way to 
label close proximity interactors in living cells and to detect transient and weak interac? ons 
with reasonable background (Roux et al., 2012; Varnaité and MacNeill, 2016). Noteworthy, 
the labeling radius is about 10 nm (Kim et al., 2014) indica? ng that spa? otemporally similar 
proteins will be labeled. Bio? n will remain a? ached to the protein even though the BirA*-
containing protein has moved further away, providing a molecular picture of the proteomic 
landscape in the cell.   
Figure 14: An overview of the BioID work? ow. Addi? on of bio? n to the cell culture media ac? vates 
the bait protein tagged with modi? ed bio? n ligase, BirA* (indicated with a green star).  Once ac? ve, 
the BirA* bio? nylates the lysine residues in close proximity. The proteins from cell lysate are a?  nity 
puri? ed using Strep-tac? n beads, trypsin digested and analyzed by LC-MS/MS. The high-con? dence 
interactors are iden? ? ed using sta? s? cal ? ltering. 
3.2  Assessment of kinase ac? vity
As the func? on of protein kinases is to transfer a phosphate group, western blo?  ng with 
an? bodies against a substrate’s phosphoserine, -threonine or -tyrosine is the most common 
and widely used method to indirectly iden? fy kinase ac? vity. This approach is very labor 
intensive, highly dependent on the speci? city and sensi? vity of the available an? bodies, and 
not directly comparable with high-throughput approaches. 
A more sensi? ve, direct approach to quan? ta? vely measure kinase ac? vity in vitro is to 
measure the incorpora? on of radiolabeled phosphate from ?-33P ATP into the substrate (Has? e 
et al., 2006). A prerequisite to the solu? on-based in vitro kinase assays is a puri? ed kinase, 
which in most cases is compared to the kinase dead mutant that abolishes ATP binding. An 
extensive study of 84 pairs of wild-type kinases and their kinase-dead counterparts (Varjosalo 
et al., 2008) con? rmed, using in vitro kinase assays, that indeed the mutated “VAIK” or “HRD” 
mo? f is essen? al for kinase ac? vity. The lysine in the “VAIK” mo? f is among the most conserved 
amino acids in all kinases as it is a central catalyzer of the phosphate transfer (Manning et al., 
2002).   
Func? onal protein microarrays are an e?  cient ‘omics’-scale tool to detect kinase-substrate 
interac? ons (Zhu et al., 2001; Mok et al., 2009). The commercially available protein microarrays 
have thousands of puri? ed proteins spo? ed onto a glass slide, providing an e?  cient means to 
iden? fy phosphoryla? on of candidate substrates for the kinases of interest when incubated 
together with radiolabeled ATP (Meng et al. 2008) (Figure 15). To date, the only large-scale 
study u? lizing protein microarrays in kinase substrate iden? ? ca? on has been performed 
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with yeast protein kinases (Fasolo et al., 2011), although the human protein microarrays are 
nowadays commercially available. 
Figure 15: Kinase substrate iden? ? ca? on on ProtoArray. A? er blocking the microarray, puri? ed 
kinase is added in the presence of 33P-ATP and incubated on slide. The unbound 33P-ATP is removed 
by rigorous washing, and an image of the microarray is exposed to an X-ray ? lm. The acquired image 
is further analyzed with ProtoArray Prospector so? ware (Invitrogen). 
Patients and Methods
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II  AIMS OF THE STUDY 
The overall aim of this thesis project was to shed light on the cellular signaling networks of 
human CMGC-protein kinases. Of special interest were the physical and func? onal interac? ons 
of these kinases in human diseases. To validate our ? ndings and further deepen the 
understanding of speci? c CMGC-kinase roles in human cancer, we focused on the func? onal 
roles of CDK8 and CDK19 within the Mediator complex in the newly iden? ? ed MED12 muta? on-
linked diseases. 
The speci? c aims in studies (I-IV) were as follows:
• To perform a global and comprehensive proteomics analysis of the signaling networks of 
the cancer-linked CMGC protein kinases (I). 
• To study the impact of MED12 cancer-associated muta? ons to the Mediator kinase module 
assembly and func? on (II-IV).
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III  MATERIALS AND METHODS 
The methods used in this thesis are summarized in this chapter. A more detailed descrip? on is 
found in the original publica? ons (I-IV). 
1.  DNA CONSTRUCTS  (I-IV)
Cloning of the DNA constructs was performed by using the Gateway® recombina? on 
technology (Thermo Fisher Scien? ? c).  The human CMGC kinase entry clones were obtained 
from the human Orfeome clone collec? on (Varjosalo et al., 2008) or from commercial 
sources (ThermoScien? ? c or Dharmacon). The MED12 mutant plasmids were created using 
the QuikChange Site-Directed Mutagenesis kit (Agilent Technologies) either to a des? na? on 
vector (Varjosalo et al., 2013b) or to a gateway pDONR221 entry clone containing wild type 
MED12 cDNA (Turunen et al., 2014).  Finally, the entry clones were transferred by Gateway® 
recombina? on into des? na? on vectors, that contained either N- or C-terminal tetracycline-
inducible double a?  nity SH-tag (Twin-Strep-tag and hemagglu? nin; pcDNA5_TO_StrepIII_HA_
GW_FRT; Varjosalo et al., 2013b) or tetracycline-inducible BirA*/Myc-tag (bio? n protein ligase 
and human c-myc; pcDNA5_TO_MYC_BirA; Heikkinen et al., 2017) (Table 1). 
Table 1: Constructs and tags used in studies. The StrepIII or BirA are always proximal to protein of 
interest, other tags (Myc or HA) distal. 
Study I Study II Study III Study IV
SH-tag
HA_StrepIII-POI (N-terminal tag) X
POI-StrepIII_HA (C-terminal tag) X X X X
BirA*/Myc-tag
POI-BirA*_Myc (C-terminal tag) X
POI= Protein Of Interest 
2.  GENERATION OF ISOGENIC, TETRACYCLINE-
INDUCIBLE, STABLE CELL LINES (I-IV)
Flp-In™ 293 T-REx cells (Invitrogen), containing an Flp Recombina? on target (FRT)-site at a 
transcrip? onally ac? ve genomic locus and expressing the Tet repressor, were u? lized in all of 
the original publica? ons (I-IV) to create a stable, inducible cell lines. Upon cotransfec? on of 
pOG44 (Invitrogen) and des? na? on vector of interest, the FLP recombinase is expressed from 
the pOG44 media? ng a homologous recombina? on event between the FRT sites integrated 
into the genome of the cell line and on the des? na? on vector. Integra? on confers hygromycin 
resistance and expression of the protein under inves? ga? on can be induced by the addi? on of 
tetracycline. This allows near intrinsic expression levels. 
The pOG44 plasmid and corresponding kinase, MED12 WT or MED12 mutant des? na? on 
vector were cotransfected into the Flp-In™ 293 T-REx cells using FuGENE 6 Transfec? on Reagent 
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(Promega) according to manufacturer’s instruc? ons. Selec? on with Hygromycin B (Thermo 
Fisher Scien? ? c) was started two days a? er the transfec? ons to create stable cell line. Cell lines 
were cultured in Dulbecco’s Modi? ed Eagle Medium (DMEM 1.5 g/l glucose) supplemented 
with 10% FBS, 2 mM L-glutamine, 50 mg/ml penicillin and 50 mg/ml streptomycin. 
3.  AFFINITY PURIFICATION OF PROTEIN COMPLEXES (I-IV)
For each pull-down experiment approximately 5×107 cells (5 x 15 cm con? uent dishes) in two 
to three biological replicates were induced with 1 ?g/ml tetracycline (Sigma) for 24 hours 
(for BioID addi? onal 50 ?M bio? n was added). A? er induc? on, cells were washed with 0.1 
mM MgCl2, 0.1 mM CaCl2 in PBS and harvested in 1 mM EDTA-PBS. Cells were pelleted by 
centrifuga? on 400 g for 5 min at 4 °C, then snap-frozen.
Cell pellets were a?  nity puri? ed either with SH-tag or BirA*/Myc-tag puri? ca? on method 
(Table 1). Strep-tag a?  nity puri? ca? on was performed as described in (Turunen et al., 2014), 
and BioID puri? ca? on with harsher condi? ons is explained in (Heikkinen et al., 2017). Brie? y, 
cells were lysed in HNN-bu? er, proteins were bound with Strep-Tac? n sepharose beads (IBA 
GmbH) in Bio-Spin chromatography columns (Bio-Rad), and bound proteins were eluted with 
D-bio? n in HNN-bu? er (I-IV). 
Obtained proteins were reduced and alkylated followed by trypsin diges? on overnight 
at 37 °C. Pep? des were quenched with tri? uoroace? c acid (TFA), puri? ed by reverse-phase 
chromatography C-18 Micro SpinColumns (Nest Group) and eluted with 0.1% TFA in 50% 
acetonitrile (ACN). Samples were vacuum dried and recons? tuted in 30 ?l bu? er A (0.1% TFA 
and 1% ACN in LC-MS grade water) and vortexed thoroughly.
4.  PROTEOMICS ANALYSIS (MASS SPECTROMETRY) (I-IV)
LC-MS/MS analysis was performed on an LTQ Orbitrap XL (I) and an Orbitrap Elite ETD Hybrid 
Ion Trap (II-IV) mass spectrometer coupled to an EASY-nLCII-system (all from Thermo Fisher 
Scien? ? c) via a nanoelectrospray ion source. The detailed mass spectrometer se?  ngs are 
described in Varjosalo et al., 2013b (I) and Turunen et al., 2014 (II-IV). 
Peak extrac? on and subsequent protein iden? ? ca? on against the human reference 
proteome of UniProtKB/SwissProt database (www.uniprot.org) were performed with XTandem 
search algorithm with the k-score plug-in (I) and Proteome Discoverer so? ware using SEQUEST 
search engine (Thermo Scien? ? c) (II-IV). 
The high con? dence protein-protein interac? ons were iden? ? ed using stringent ? ltering 
against CRAPome contaminant database (Mellacheruvu et al., 2013). The bait normalized 
rela? ve protein abundances (% to the bait) were calculated from the spectral counts. Each 
average and standard devia? on was calculated from 3 biological replicates. Sta? s? cal di? erence 
of the nuclear pore protein abundance of individual mutant versus WT were calculated with 
Student’s t-test.
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5.  IMMUNOPRECIPITATION AND WESTERN BLOTTING (I-IV)
To analyze the protein-protein interac? ons with co-immunoprecipita? on (I) transfected 
HEK293T cells were lysed 24 hours a? er transfec? on in HNN bu? er supplemented with 0.5% 
NP-40, 1.5 mM NaVO3, 0.5 mM PMSF and protease inhibitor cocktail for mammalian cells 
(Sigma). Cleared lysate was incubated with an? -HA agarose beads (Sigma) for 1 hour on a 
rotatory wheel at 4 °C. A? er incuba? on beads were washed ? ve ? mes with lysis bu? er, and 
complexes were eluted in Laemmli Sample Bu? er. Denatured samples were electrophorized 
on 7.5% SDS-PAGE gels and transferred to nitrocellulose membranes (Whatman GmbH). 
Immunoprecipitated proteins were detected wither with an? -HA (HA-11, Covance) or an? -V5 
(Invitrogen) primary and horseradish peroxidase (HRP) -conjugated secondary an? bodies (an? -
mouse HRP 31450, Pierce). Signals were visualized by chemiluminescence using Amersham ECL 
Western Blo?  ng analysis system (GE Healthcare).  
The expression of constructs upon tetracycline induc? on was also con? rmed by western 
blo?  ng (I-IV). Proteins were separated on 10% SDS-PAGE gel, transferred to nitrocellulose 
membranes and detected with an? bodies listed in Table 2 as described above. 
6.  BIMOLECULAR FLUORESCENCE COMPLEMENTATION 
(BiFC) ASSAYS (I)
The bimolecular ? uorescence complementa? on (BiFC) can be u? lized to study protein-protein 
interac? ons in living cells. The technique is based on the observa? on, that two non-? uorescent 
frac? ons of a ? uorescent protein form a ? uorescent complex upon associa? on (Kerppola, 
2006). To validate the bait-prey interac? ons with the BiFC assay, the bait protein (a kinase) 
was tagged with N-terminal fragment of GFP, and the interac? ng prey protein with C-terminal 
fragment of GFP. When the bait and prey protein are in close proximity, the GFP molecule is 
recons? tuted and GFP signal can be visualized. pBiFC BAIT and -ORF vectors were a kind gi?  
from Dr. Darren Saunders (Vancouver, Canada). For analysis HeLa cells were seeded onto glass 
coverslips and transfected with Bait-V1_mCherry and Prey-V2_Cerulean. 24 hours a? er the 
transfec? on cells were ? xed with 4% paraformaldehyde, permeabilized and their nuclei were 
stained with TOTO-3 (Invitrogen). A? er washing coverslips were mounted with Vectashield® 
hardening moun? ng media (Vector Laboratories) and staining was visualized with confocal 
microscopy. 
7.  IMMUNOFLUORESCENCE (IV)
The iden? ? ed MED12 nuclear localiza? on signal (NLS) was validated by cloning the MED12-
NLS sequence (amino acids 11-20; HRPLKRPRLG) into pcDNA5_TO_StrepIII_HA_GW_FRT 
vector (Varjosalo et al., 2013b) containing green ? uorescent protein (GFP). This construct was 
transfected using HelaFect (OZbiosciences) into HeLa cells plated on coverslips. The following 
day, the cells were ? xed with 4% PFA, permeabilized with 0.1% Triton-X and stained with 
Alexa Fluor® 568 Phalloidin (Thermo Fisher Scien? ? c). A? er rinsing, coverslips were mounted 
with Vectashield® moun? ng media (Vector Laboratories) containing DAPI (4’, 6-diamidino-2-
phenylindole) to visualize the nuclei. Cells were visualized with confocal microscopy. 
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Table 2: An? bodies and dyes used in studies.
An? body / Dye Method 
used in
Manufacturer Catalog number Study
Dyes
TOTO-3 BiFC Invitrogen T3604 I
DAPI (4’, 6-diamidino-2-
phenylindole)
IF Sigma D9542 IV
AlexaFluor® 568 Phalloidin IF Thermo Fisher Scien? ? c A12380 III, IV
Primary an? bodies
an? -HA (HA-11) WB, co-IP, 
IF
Covance MMS-101R I, III, 
IV
an? -V5 WB, co-IP Invitrogen 46-0705 I
an? -GAPDH WB Abcam Ab37168 III
Secondary an? bodies
an? -mouse HRP WB GE Healthcare NA931 IV
an? -mouse HRP WB Pierce 31430 I
An? -rabbit HRP WB Sigma-Aldrich A0545 III
an? -mouse Alexa488 IF Thermo Fisher Scien? ? c A11001 III, IV
IF= immuno? uorescence; WB= Western Blo?  ng; co-IP= co-immunoprecipita? on
8.  IN VITRO KINASE ASSAYS (I)
Kinase substrates were iden? ? ed using ProtoArray® human protein microarrays (Thermo 
Fischer Scien? ? c). A? er blocking the microarray was incubated with 50 nM kinase in the 
presence of 33P-ATP (PerkinElmer). Unbound radiolabeled ATP was removed by washing, and 
a? er drying the microarray was exposed to Hyper? lm MP (GE Healthcare). Data was analyzed 
with ProtoArray® Prospector software (Thermo Fischer Scien? ? c).  
?
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IV  RESULTS AND DISCUSSION 
1.  THE PROTEIN INTERACTION LANDSCAPE OF THE HUMAN 
 CMGC KINASE GROUP (I)
The recently developed AP-MS method (Gla? er et al., 2009) was u? lized in the study of CMGC 
kinase complexes to systema? cally determine the physical (protein-protein) interac? ons for 57 
CMGC kinases. These selected kinases included members from all CMGC kinase subfamilies 
(Figure 16). A? er genera? on of the isogenic cell lines, expression of the tagged kinases was 
induced, cell pellets harvested, and a?  nity-puri? ed. A? er trypsin diges? on and subsequent 
C18-puri? ca? on the samples were subjected to LC-MS/MS analysis. The resul? ng data-? les 
were searched against the human reference proteome, and a? er sta? s? cal ? ltering using 
SAINT algorithm (Choi et al., 2011) high con? dence interac? ng proteins (HCI) were iden? ? ed. 
In total 481 interac? ng proteins were iden? ? ed forming 652 interac? ons. When our data was 
compared with publicly available interac? on data, 531 novel interac? ons within the CMGC 
kinases were iden? ? ed. Not surprisingly, most of the novel interac? ons iden? ? ed in this 
study clustered in the less-studied kinase subfamilies such as DYRK, SRPK or CLK (Figure 16). 
The enriched GO classi? ca? ons (GO Biological Processes, GO-BP) among the HCIs were cell 
communica? on, cell growth, and cell cycle as many of the CMGC kinases have an established 
role in cell-cycle regula? on and cellular signaling (Figure 16). Also the poorly studied kinases 
such as DYRKs could be assigned a dis? nct, previously unknown cellular func? on. 
Figure 16: CMGC family members and their protein-protein interac? ons. A) Network model of 
CMGC kinase interac? ons. The CMGC families are shown on the outer rim of the network, and 
organized based on their sequence similarity. B) Novel (iden? ? ed in this study) and known (from 
databases) interac? ons of the CMGC kinases. (Adapted from Varjosalo et al., 2013b)
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Selec? on of the obtained interac? ons was validated via bimolecular ? uorescence 
complementa? on (BiFC) assays in HeLa cells and by co-immunoprecipita? on of HEK293T cells. 
High number of tested interac? ons were validated with either of the methods (23/23) or with 
both methods (19/23). On average, kinases form interac? ons with mul? ple partners, but the 
number of interac? ons per bait varies greatly between the CMGC kinase families (CDKL and 
RCK had only a few interactors, whereas SRPKs showed over three ? mes higher bait-to-prey 
ra? o compared to other CMGC kinases). Upon closer inspec? on it was discovered that related 
kinases o? en have mul? ple common HCIs, but some kinases can form unique, highly speci? c 
complexes. An excellent example of a kinase subfamily presen? ng both shared and speci? c 
interac? ons is GSK3? and GSK3?, where only GSK3? was observed in complex with ?-catenin 
and APC further suppor? ng the func? onal role of GSK3? in Wnt signaling.  
As an example of the high speci? city and sensi? vity of the u? lized work? ow, we no? ced 
that three members of the CDK family (CDK7, CDK8, CDK19) form complexes with HCIs involved 
in transcrip? on ini? a? on – an observa? on well in-line with the current literature. General 
transcrip? on factor TFIIHH complex subunits were exclusively revealed in the CDK7 interactome. 
On the other hand, CDK8 and CDK19 were shown to interact with mul? ple Mediator complex 
components, providing, at the ? me, the most complete picture of interac? ons between CDK8, 
CDK19 and di? erent MED subunits (Figure 17).  
Figure 17: CDK8 and CDK19 form interac? ons with mul? ple Mediator subunits. The Mediator 
complex associates either with CDK8 or CDK19. Blue edges indicate interac? ons iden? ? ed in this 
study, while known interac? ons are visualized with black do? ed lines. (Adapted from Varjosalo et 
al., 2013b) 
In addi? on, a previously unknown kinase-kinase interac? on subnetwork in the CMGC 
interactome was found, as almost half of the CMGC kinases showed a preference to interact 
with protein kinases. Interes? ng observa? on was the enrichment of kinase-kinase interac? ons 
within the CMGC kinase family (44 out of over 100 iden? ? ed kinase-kinase interac? ons), 
followed by interac? ons formed with Ca2+/calmodulin-dependent protein kinase (CAMK; 24 
interac? ons) and protein kinase A, G, and C (AGC; 13 interac? ons) groups.  
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To further characterize the func? onal, kinase-substrate, signaling networks, 
phosphopep? des were iden? ? ed from the AP-MS data. Based on our phosphopep? de data, 
and data available from public databases a hypothe? cal network of substrates and their 
upstream kinases, u? lizing known kinase-substrate data, was created. This network was 
further merged with the HCI AP-MS data to iden? fy poten? al high con? dence kinase-substrate 
interac? ons. This approach iden? ? ed numerous kinases and their candidate substrates for 
kinase subfamilies such as GSK, CDK or MAPK. For SRPKs a di? erent approach was selected, 
as substrate predic? on tools, due to the low number of known substrates, did not cover these 
kinases. The in vitro kinases assays (IVK) were used to demonstrate the kinase-substrate 
associa? on for SRPKs. A? er combining the data from IVK and AP-MS, a network of RNA splicing 
or processing proteins was observed.  
Searching this proteomic CMGC kinase dataset against gene? c human disease databases 
(OMIM and COSMIC) revealed 91 disease-associated proteins (DAPs) forming 143 interac? ons 
(108 novel) with CMGC kinases. The most pronounced disease class was cancer. The clustering 
of disease phenotypes with speci? c kinase families and complexes iden? ? ed ? ve kinase 
complex clusters, where the preys were linked to a speci? c disease phenotype. In total 43 
kinase-associated proteins could be linked to various forms of human cancer, showing roughly 
three ? mes higher frequency than expected from a random network of similar features (Figure 
18), thus, several CMGC kinases could be classi? ed as ‘cancer-hubs’. Remarkably, some ‘hubs’ 
were associated with proteins linked to a speci? c type of cancer. Good examples of speci? c 
cancer-linked proteins are proteins iden? ? ed in complexes with CDK9, and mostly linked to 
acute lymphoplas? c leukemia (ALL) and acute myeloid leukemia (AML) (Figure 18).  
                      
Figure 18: Complexes of CMGC kinases and disease associated proteins. A) Enrichment of cancer 
associated proteins in CMGC network. The number of cancer proteins in CMGC interactome was 
43 (dashed line).  B) CDK9 showed an enrichment of interac? ons with proteins mutated in ALL. 
Known interac? ons are visualized with blue edges, novel interac? ons are indicated with red edges. 
(Adapted from Varjosalo et al., 2013b)
To conclude, known interac? ons were con? rmed and several novel interac? ons iden? ? ed of 
the CMGC kinases leading to be? er understanding of their func? onal roles in mammalian 
cells. The phosphopep? de analysis iden? ? ed mul? ple candidate substrates also for the poorly 
studied CMGC kinases, providing a good star? ng point for future experiments. The interac? ons 
of CDK8/19 and Mediator components were also comprehensively mapped, proving evidence 
that the approach is robust and sensi? ve. 
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Overall, the poorly studied subfamilies were overrepresented in this kinase interactome 
indica? ng that the database informa? on is biased towards the well-known families. This is not 
surprising, but points out the need for systema? c proteomics studies to be? er characterize 
these proteins and their cellular func? ons. This study showed more than 100 physical 
interac? ons of CMGC kinases and human DAPs not listed in public databases. Several diseases 
clustered around speci? c kinase families, hin? ng that these kinases might serve as future 
targets for the development of new therapeu? c agents. 
2.  UTERINE LEIOMYOMA-LINKED MED12 MUTATIONS 
 DISRUPT MEDIATOR-ASSOCIATED CDK ACTIVITY (II)
Although benign, leiomyomas are among the most common tumors in women of reproduc? ve 
age, and the leading cause of hysterectomies worldwide (Ordulu 2016). Informa? on about 
the molecular mechanisms underlying the tumor forma? on has remained sparse, but gene? c 
factors have been implicated to have a role in tumorigenesis (Ordulu, 2016). Recently, whole-
exome sequencing revealed that muta? ons in exon 2 of MED12 occur at high frequency 
(~70%) in uterine leiomyomas (Makinen et al., 2011). The impact of the most common uterine 
leiomyoma -linked MED12 muta? on, G44D, to the func? ons of CDKs and the Mediator kinase 
module in tumorigenesis was studied using the AP-MS method. In AP-MS analysis, the G44D 
muta? on showed reduced binding to the Mediator kinase module components cyclin C, 
CDK8, and CDK19, when compared to wild type (WT) MED12 (Figure 21). Interac? ons with 
other Mediator subunits remained una? ected. The reduced associa? on of G44D with CDK8 
and CDK19 was con? rmed by co-immunoprecipita? on and western blo?  ng analysis. Other 
leiomyoma-linked muta? ons (L36R, Q34P, G44S) were also shown to lose their interac? ons 
with the Mediator kinase module. 
To determine the mechanism behind the disrupted interac? on between MED12 and cyclin 
C-CDK8, six MED12 constructs of variable lengths were designed. Recombinant proteins of 
these constructs and the full-length WT MED12 were produced and immunoprecipitated in the 
presence of CDK8 and cyclin C. Kinase ac? vity of CDK8 was also monitored. These experiments 
mapped the cyclin C-CDK8 binding and ac? va? on domain of MED12 within its ? rst 100 amino 
acids. Next, MED12 was shown to bind to cyclin C, which further binds to CDK8. MED12 also 
presented binding to MED13 that bound neither to cyclin C or CDK8. Dis? nct binding surfaces 
in cyclin C for MED12 and CDK8 were revealed, and the cyclin C surface groove was further 
iden? ? ed as the main MED12 binding interface leading to CDK8 ac? va? on. Overall, these 
results show that MED12 ? rst binds to cyclin C, which in turn binds to CDK8, revealing the 
molecular basis for the loss of interac? ons. 
Taken together, this study shows that MED12 muta? ons in uterine leiomyoma severely 
compromise the interac? ons with Mediator kinase module components CDK8 and cyclin 
C. Importantly, the ? rst 100 amino acids in MED12 were iden? ? ed crucial for binding and 
ac? va? on of CDK8/cyclin C, sugges? ng a leiomyoma-linked func? onal Mediator kinase module 
defect contribu? ng to the forma? on of these tumors. As uterine leiomyomas globally a? ect 
hundreds of millions of women, our ? nding is an important star? ng point for the design of 
targeted therapies.  
Results and Discussion
33
3. SOMATIC MED12 MUTATIONS IN PROSTATE CANCER AND 
 UTERINE LEIOMYOMAS PROMOTE TUMORIGENESIS 
 THROUGH DISTINCT MECHANISMS (III) 
Recently, inspec? on of MED12 muta? ons in exon 26 that lead to discovery of L1224F 
subs? tu? on were described in prostate cancer in 5 out of 152 pa? ents (Barbieri et al., 2012). 
To analyze the presence of this MED12 L1224F muta? on in Finnish pa? ent samples, a sample 
set of nearly 800 tumors was analyzed. Within this set L1224F muta? on was iden? ? ed in one 
pa? ent.  
To elucidate the func? onal role of this prostate cancer-speci? c muta? on in the context 
of Mediator kinase module, isogenic HEK293 cell lines expressing MED12 L1224F and MED12 
WT were generated, and their protein-protein interac? ons analyzed with AP-MS. The L1224F 
mutant was able to interact with cyclin C, CDK8 and CDK19, and presented similar CDK8 kinase 
ac? vity as MED12 WT. Instead, L1224F had reduced interac? ons with MED13, MED13L, MED17, 
MED1, MED14, MED15, and MED24 (Figure 19). Changes in interac? ons outside the Mediator 
complex were not observed. Cellular localiza? on of both L1224F and G44D mutant MED12 
remained mainly nuclear similar to WT MED12. 
Figure 19. Interac? ons of MED12 WT, L1224F, and G44D. The prostate cancer-speci? c MED12 
L1224F muta? on presented reduced binding to MED13. However, interac? ons with other 
components of the Mediator kinase module remained at a level comparable to MED12 WT. The 
reduced interac? ons are indicated with dashed lines, whereas solid lines indicate interac? ons that 
remained similar to WT (average fold change at least 0.4). Color-coding of the Mediator head, tail, 
middle and kinase domain subunits according to Figure 10. (Adapted from Kampjarvi et al., 2016)
In summary, our results highlight the func? onal di? erences of MED12 mutants in uterine 
leiomyoma and prostate cancer by revealing the di? erent interac? on pro? les of the prostate-
speci? c MED12 L1224F muta? on and the uterine leiomyoma MED12 hotspot muta? on G44D. 
The interac? on pro? le of L1224F was also biologically relevant, as interac? ons with MED1 
and MED15 were decreased. MED1 has been reported to promote growth and survival of 
cancer cells (Jin et al., 2012; Vijayvargia et al., 2007; Jin et al., 2013), and overexpression of 
MED15 has been detected in castra? on-resistant prostate cancer (Shaikhibrahim et al., 2014a; 
MED1
MED17
MED14
MED15
MED24
MED12
L1224F
G44D
MED13
cyclin C
CDK8/19
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Shaikhibrahim et al., 2014b). At the end of the day, to be able to establish a causal rela? onship 
between an observed muta? on and a disease, three criteria must be met: 1) genotype 
is not occurring just by change in popula? on, 2) the gene? c variant must impair or destroy 
gene expression or the func? on of the protein product, and 3) the causal rela? onship must 
be con? rmed in a relevant model in vitro or in vivo (Casanova et al., 2014). Thus, to be? er 
understand the role in tumorigenesis and to con? rm the causal role of MED12 L1224F muta? on 
in prostate cancer, further studies with for example MED12 muta? on-posi? ve cells would be 
needed.  
4.  SOMATIC MED12 NONSENSE MUTATION ESCAPES 
mRNA DECAY AND REVEALS A MOTIF REQUIRED FOR 
NUCLEAR ENTRY ?IV?
The ? rst MED12 exon 1 nonsense muta? on (c.97G>T, p.E33X) was iden? ? ed in a T-ALL pa? ent 
through exome sequencing (Kontro et al., 2014). Previously, MED12 missense muta? ons 
a? ec? ng site E33 were observed in chronic lymphocy? c leukemia (CLL) samples (Kampjarvi 
et al., 2015). In study IV, this T-ALL nonsense muta? on, which was predicted to result in a 
truncated protein, was validated in the genomic DNA of the pa? ent.  
The func? onal e? ects of the MED12 E33X muta? on on translated protein products, its 
localiza? on, and protein-protein interac? ons were studied u? lizing the stable, isogenic, 
inducible HEK293 cell lines. In western blot analysis using an an? -HA an? body, the molecular 
weight of the MED12 E33X was clearly smaller compared to the WT MED12 or missense 
mutants G44D (uterine leiomyoma hotspot) or E33K (CLL hotspot). An interes? ng observa? on 
was, that an N-terminal MED12 an? body could not recognize the E33X mutant in western blot. 
Mass spectrometry analysis of the E33X MED12 pep? des further validated this observa? on as 
the ? rst pep? de iden? ? ed from the E33X AP-MS samples was ranging from amino acid 163 
to amino acid 174 (Figure 20). MED12 alanine mutants M154A, M162A and M154A&M162A 
validated M154 as the transla? on ini? a? on site in the E33X mutant. Thus, the E33X MED12 
mutant was shown to escape nonsense mediated mRNA decay and lead to an N-terminally 
truncated protein.
Figure 20: The iden? ? ed pep? des of MED12 E33X and MED12 WT. The pep? des iden? ? ed with 
mass spectrometry from MED12 WT are indicated with green, and red is used for MED12 E33X 
pep? des. The alterna? ve transla? on start sites, M154 and M162 are wri? en in red.  (Adapted and 
modi? ed from Heikkinen et al., 2017)
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The AP-MS analysis revealed that the MED12 E33X mutant fails to interact with all Mediator 
complex components (Figure 21). On the contrary, the missense muta? on E33K resembled 
the uterine leiomyoma speci? c G44D mutant (Turunen et al., 2014) presen? ng diminished 
interac? ons between MED12 and the Mediator kinase module subunits CDK8, CDK19, and 
cyclin C. Other Mediator complex interac? ons were unimpaired (Figure 21).    
Figure 21: AP-MS results from MED12 WT, G44D, E33K, and E33X. The N-terminally truncated 
MED12 mutant E33X loses interac? ons with Mediator complex components, whereas the 
uterine leiomyoma hotspot, G44D, shows reduced interac? ons with the Mediator kinase module 
components CDK8, CDK19, and cyclin C (CCNC). Missense mutant E33K phenocopies the G44D 
mutant. (Adapted from Heikkinen et al., 2017) 
Immuno? uorescent staining revealed mislocaliza? on of the N-terminally truncated E33X 
to the cytoplasm, while MED12 WT and E33K were nuclear. This observa? on suggested that 
MED12 might have an N-terminal sequence important for nuclear localiza? on; thus, four in 
silico predic? on tools were u? lized to analyze the presence of a nuclear localiza? on signal (NLS) 
in MED12. All of these tools suggested an NLS in the N-terminus of MED12 between amino 
acids 13-19. Two alanine mutant constructs of di? erent lengths were generated (NLS1, amino 
acids 13-16; NLS2, amino acids 13-19) to disrupt the predicted NLS. Both constructs produced 
a protein localizing to the cytoplasm and had severely disrupted protein-protein interac? ons 
with the Mediator complex similar to E33X. Also, a fusion construct of MED12 amino acids 
11-20 to GFP showed nuclear localiza? on. 
To reveal the func? onal mechanism of MED12 nuclear entry, we u? lized the BioID proximity 
labelling. In the BioID analysis MED12 interac? ons with impor? ns and nuclear pore complex 
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(NPC) components were detected. The E33X mutant presented either lost or diminished 
interac? ons with nuclear basket components, and impor? n-?-proteins similar to NLS1 and 
NLS2 mutants (Figure 22). Intriguingly, E33X and NLS mutants retained or even increased their 
interac? on with impor? n-? compared to the MED12 WT. This suggests that MED12 mutants 
fail to bind to impor? n-? and enter the NPC central channel, thus remaining in the cytoplasm.  
Figure 22: BioID analysis of MED12 WT, NLS1, NLS2, and E33X. A) Interac? ons of MED12 and 
proteins of the nuclear import machinery were iden? ? ed in BioID analysis. E33X has reduced 
interac? ons with impor? n ? proteins (IMA1, IMA4, and IMA7), and dimished interac? ons with 
the nuclear ring proteins (NUP50, NUP153, and TPR).  B) Based on the BioID results a schema? c 
presenta? on of the nuclear entry through the NPC could be built for MED12 WT (green arrow) and 
MED12 E33X (red arrow).  (Adapted from Heikkinen et al., 2017)
In our previous work, the binding site for cyclin C in the N-terminus of MED12 was iden? ? ed 
(Turunen et al., 2014), but hitherto the MED12 func? onal domains have remained rather 
uncharacterized outside the SOX9, ?-catenin and Gli3 binding regions in the PQL domain (Zhou 
et al., 2002; Kim et al., 2006; Zhou et al., 2006). Now a nuclear localiza? on signal was iden? ? ed 
in the MED12 E33X T-ALL mutant producing a protein lacking the N-terminus of MED12. 
This truncated protein had severely impaired interac? ons with other Mediator complex 
components due to cellular mislocaliza? on in the cytoplasm. To sum up, these results indicate 
that the nuclear entry of MED12 is essen? al for the interac? ons with other kinase module 
components and, further, for kinase ac? vity. MED12 was recently iden? ? ed as necessary for 
normal hematopoiesis (Aranda-Orgilles et al., 2016), giving room for specula? on of the role of 
MED12 in hematological malignancies.      
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V  CONCLUSIONS AND FUTURE PROSPECTS
The overall aim of this thesis was to provide a systema? c characteriza? on of a protein kinase 
family called CMGC. This family consists of 62 members of 8 subfamilies presen? ng both well-
studied kinases as well as kinases without a known cellular func? on. Most of the kinases in 
this family are known to be important regulators of cell cycle progression and responders to 
autocrine or paracrine signals for determining func? ons such as cell entry into senescence 
or apoptosis. All of these processes are of crucial importance to normal cells. Cancer, simply 
put, is uncontrolled growth (division) of abnormal cells, where protein kinases are o? en 
found overexpressed or overac? ve. Cancer incidence rate is related to age, which is at least 
partly explained by the slow accumula? on of muta? ons in the genes controlling cellular 
processes. Most cellular processes rely on the correct phosphoryla? on of substrates (or their 
dephoshoryla? on), and gene? c and epigene? c events leading to aberrant regula? on of protein 
kinases, not surprisingly, are implicated in mul? ple cancers (Cohen, 2002; Knight et al., 2010; 
Abbassi et al., 2015; Gross et al., 2015). 
It is, therefore, not surprising that the systems wide iden? ? ca? on of the protein-protein 
interac? ons of the CMGC kinases revealed physical interac? ons mostly with cancer-associated 
proteins (I). Our studies also suggest a common mechanism for MED12 muta? ons contribu? ng 
to leiomyoma forma? on, and highlight the func? onal di? erences of MED12 mutants in uterine 
? broids and prostate cancer (II-III). We also iden? ? ed the novel MED12 NLS, and showed that 
the correct localiza? on and subunit assembly is essen? al for proper func? on of the Mediator 
kinase module (IV). 
The Mediator kinase module components and mul? ple other members of the CMGC 
kinase family have been linked to mul? ple human malignancies, and they can be considered as 
an important target for future therapeu? c interven? ons. Based on the high number of kinase 
inhibitors in di? erent stages of pre-clinical and clinical trials, either as single or combina? on 
therapies, they possess vast poten? al in the treatment of a range of human pathologies. To date, 
Mediator subunits have not been targeted, but a recent study (Al-Hendy et al., 2017) showed 
that the knockdown of MED12 in uterine leiomyoma cells slowed down cell prolifera? on and 
decreased the expression levels of CDK1, CDK2, and cyclin D1. 
As men? oned earlier, data in public collec? ons are biased towards the most-studied 
kinases, and only recently the HUGO Gene Nomenclature Commi? ee (HGNC) (h? p://www.
genenames.org/) renamed and uni? ed the names of CDK subfamily members. The systema? c 
analysis of the func? ons of these kinases in the cell has been challenging and only the recent 
advances of the ‘omics’ techniques has made it possible to study kinases as large en? ? es in 
their physiological environment. AP-MS and the applica? on of BioID-method in the study of 
kinase func? ons in pathological condi? ons will, without a doubt, shed more light on the biology 
of these cellular components. The global and complete analysis of CMGC kinase func? onal 
interac? ons, substrate-speci? ci? es, phosphoryla? on events and dynamics of these networks 
presents an important future goal for be? er understanding of the mechanisms of ac? on in 
health and disease. 
Finally, it may be concluded, that understanding the regulatory diversity and complexity 
of the human kinome is of utmost importance to develop new well-tolerated, speci? c, potent 
pharmacological interven? ons for the treatment of neurodegenera? ve diseases and mul? ple 
cancers. 
Conclusions and Future Prospects
38
VI  ACKNOWLEDGEMENTS
This work began at the Ins? tute of Molecular Systems Biology, Swiss Ins? tute of Technology 
(ETH) Zurich, and was further con? nued at the Ins? tute of Biotechnology, University of Helsinki. 
I would like to thank both ins? tutes for providing such excellent infrastructures, which enabled 
this work to be carried out and completed. I would like to express my warmest thanks to Anita 
Tienhaara from the Doctoral School in Health Sciences and Erkki Raulo from Integra? ve Life 
Science (ILS) Doctoral Program for providing support during my years in Helsinki as a graduate 
student. The ILS Doctoral Program is also acknowledged for providing valuable post-graduate 
courses, teaching opportuni? es, and extracurricular ac? vi? es. I have been ? nancially supported 
by grants from The Finnish Cancer Founda? on, Emil Aaltonen Founda? on, and FinnProt.
My greatest thanks belong to Dr Markku Varjosalo, who supervised all the studies 
presented in this PhD thesis. I ? rst started as an undergraduate student in the Gstaiger 
Laboratory at the ETH Zurich under Markku’s supervision – a co-opera? on so frui? ul that it 
was further con? nued in Finland. During these years you have provided me with interes? ng 
research ques? ons and endless support. I am s? ll amazed of the depth and extent of your 
knowledge. Your never-ending enthusiasm for science has given me the strength to con? nue 
and restored my naïve beliefe in science. 
I sincerely thank my thesis commi? ee members Professor Sarah Butcher and Professor 
Juha Kere, for encouragement, ? exibility and valuable advice. Sarah Butcher is also thanked for 
general support and all the non-scien? ? c talks over co? ee. I would also like to thank Professor 
Kari Keinänen, who was very suppor? ve even when the last minute changes almost happened. 
Dr Vesa Hytönen and Dr Johan Peränen are thanked for careful reviewing of this thesis and 
their construc? ve comments. 
I want to thank all my co-authors and collaborators for their contribu? ons. I especially 
wish to thank Ma? hias Gstaiger and Audrey van Drogen for their warm welcome in the 
laboratory at ETHZ. It was a pleasure to work with you. I am grateful to Helka Nurkkala for 
performing important experiments with the CMGC kinases, when I was engaged elsewhere. 
Most of the published studies are results of frui? ul collabora? on with the Vahteristo laboratory 
– without Ka?  Kämpjärvi, Tuomas Heikkinen and Pia Vahteristo it would have been impossible 
to complete this work. Mikko Turunen is also thanked for his e? orts in revealing the biology of 
the MED12 uterine leiomyoma muta? ons. 
I wish to thank all the members of Varjosalo Laboratory: Sini, Helka, Tiina, Leena, Fitsum, 
Liu, Ma? as, Kari, Jaakko, Carolin, and Vera. It truly has been a pleasure and priviledge to work 
with you! I especially want to thank SINI and Tiina for sharing the great sense of humor! …and 
Kari and Vera for not following… Liu I want to thank for the comedy in the lab; thanks to you I 
will always have long legs and cheap hair. 
The Lunch Crew (Tommi, Anne-Mari, Sini, Tiina and Kari) is warmly thanked for all the 
refreshing chats and ideas of MitäTänäänSyötäisiin. Pasi, Tommi and Petri are thanked for their 
professional help and assistance to various problems. Your work is highly valued!
I am grateful for Julie and Tiina for carefully reading and commen? ng on the very ? rst 
version of this thesis. Julie, you have always been there for me, and we have experienced some 
true adventures together. I wish to thank Julie also for checking the grammar and proofreading. 
Acknowledgements
39
I wish to thank my family and friends for always believing in me and suppor? ng me. Haluan 
kii? ää äi? ä ja Eskoa kärsivällisyydestä ja osallistumisesta pitkään ja mutkikkaaseen opin? eheni. 
Ole? e aina kannustaneet ja opastaneet minua eteenpäin jä? äen kuitenkin valinnanvapauden. 
Marjo ja Jyrki perheineen ovat olleet mukana useimmissa käänteissä. Kiitos, e? ä ole? e 
jaksaneet olla kiinnostuneita projekteistani. Tuula on seurannut kasvuani Sylvesteriä kantavasta 
taaperosta aikuiseksi, ja toiminut taustatukena kun sitä on tarvi? u. I would like to thank Sonja, 
the KÄDI, for support (literally) and keeping me ? t. Thanks to your sense of humor our training 
moments have been special. Simply, to summarize my gra? tude to my extended family: You are 
the best! 
Finally, the most important thank you, hugs and kisses go to Markku and Emma for love, 
support and understanding.
Vantaa, May 2017
Acknowledgements
40
VII REFERENCES
Abbassi, R., Johns, T. G., Kassiou, M., and Munoz, L., DYRK1A in neurodegenera? on and cancer: Molecular 
basis and clinical implica? ons. Pharmacol Ther 151, 87 (2015).
Aikawa, Y. et al., Roles of HIPK1 and HIPK2 in AML1- and p300-dependent transcrip? on, hematopoiesis 
and blood vessel forma? on. EMBO J 25 (17), 3955 (2006).
Al-Hendy, A. et al., Silencing Med12 Gene Reduces Prolifera? on of Human Leiomyoma Cells Mediated via 
Wnt/beta-Catenin Signaling Pathway. Endocrinology 158 (3), 592 (2017).
Allen, B. L. and Taatjes, D. J., The Mediator complex: a central integrator of transcrip? on. Nat Rev Mol Cell 
Biol 16 (3), 155 (2015).
Arai, S. et al., Novel homeodomain-interac? ng protein kinase family member, HIPK4, phosphorylates 
human p53 at serine 9. FEBS Le?  581 (29), 5649 (2007).
Aranda, S., Laguna, A., and de la Luna, S., DYRK family of protein kinases: evolu? onary rela? onships, 
biochemical proper? es, and func? onal roles. FASEB J 25 (2), 449 (2011).
Aranda-Orgilles, B. et al., MED12 Regulates HSC-Speci? c Enhancers Independently of Mediator Kinase 
Ac? vity to Control Hematopoiesis. Cell Stem Cell 19 (6), 784 (2016).
Bancerek, J. et al., CDK8 kinase phosphorylates transcrip? on factor STAT1 to selec? vely regulate the 
interferon response. Immunity 38 (2), 250 (2013).
Barbieri, C. E. et al., Exome sequencing iden? ? es recurrent SPOP, FOXA1 and MED12 muta? ons in 
prostate cancer. Nat Genet 44 (6), 685 (2012).
Barriere, C. et al., Mice thrive without Cdk4 and Cdk2. Mol Oncol 1 (1), 72 (2007).
Beaver, J. A. et al., FDA Approval: Palbociclib for the Treatment of Postmenopausal Pa? ents with Estrogen 
Receptor-Posi? ve, HER2-Nega? ve Metasta? c Breast Cancer. Clin Cancer Res 21 (21), 4760 (2015).
Berthet, C. et al., Cdk2 knockout mice are viable. Curr Biol 13 (20), 1775 (2003).
Bogoyevitch, M. A. et al., c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. 
Biochim Biophys Acta 1804 (3), 463 (2010).
Brinkkoe? er, P. T. et al., Cyclin I ac? vates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmito? c 
mouse cells. J Clin Invest 119 (10), 3089 (2009).
Bullock, A. N. et al., Kinase domain inser? ons de? ne dis? nct roles of CLK kinases in SR protein 
phosphoryla? on. Structure 17 (3), 352 (2009).
Buro? o, M., Chiou, V. L., Lee, J. M., and Kohn, E. C., The MAPK pathway across di? erent malignancies: a 
new perspec? ve. Cancer 120 (22), 3446 (2014).
Calarco, J. A. et al., Regula? on of vertebrate nervous system alterna? ve splicing and development by an 
SR-related protein. Cell 138 (5), 898 (2009).
Cargnello, M. and Roux, P. P., Ac? va? on and func? on of the MAPKs and their substrates, the MAPK-
ac? vated protein kinases. Microbiol Mol Biol Rev 75 (1), 50 (2011).
Casanova, J. L. et al., Guidelines for gene? c studies in single pa? ents: lessons from primary 
immunode? ciencies. J Exp Med 211 (11), 2137 (2014).
Chaput, D., Kirouac, L., Stevens, S. M., Jr., and Padmanabhan, J., Poten? al role of PCTAIRE-2, PCTAIRE-3 
and P-Histone H4 in amyloid precursor protein-dependent Alzheimer pathology. Oncotarget 7 (8), 8481 
(2016).
Chen, J. Y., Lin, J. R., Tsai, F. C., and Meyer, T., Dosage of Dyrk1a shi? s cells within a p21-cyclin D1 signaling 
map to control the decision to enter the cell cycle. Mol Cell 52 (1), 87 (2013).
Chen, T., Wu, D., Moskaluk, C. A., and Fu, Z., Dis? nct expression pa? erns of ICK/MAK/MOK protein 
kinases in the intes? ne implicate func? onal diversity. PLoS One 8 (11), e79359 (2013).
Choi, H. et al., SAINT: probabilis? c scoring of a?  nity puri? ca? on-mass spectrometry data. Nat Methods 
8 (1), 70 (2011).
Clark, A. D., Oldenbroek, M., and Boyer, T. G., Mediator kinase module and human tumorigenesis. Crit 
Rev Biochem Mol Biol 50 (5), 393 (2015).
Cohen, P., Protein kinases--the major drug targets of the twenty-? rst century? Nat Rev Drug Discov 1 (4), 
309 (2002).
Cole, A. R. et al., GSK-3 phosphoryla? on of the Alzheimer epitope within collapsin response mediator 
proteins regulates axon elonga? on in primary neurons. J Biol Chem 279 (48), 50176 (2004).
Cormier, K. W. and Woodge? , J. R., Recent advances in understanding the cellular roles of GSK-3. 
F1000Res 6 (2017).
References
41
Cuadrado, A. and Nebreda, A. R., Mechanisms and func? ons of p38 MAPK signalling. Biochem J 429 (3), 
403 (2010).
De la Torre, R. et al., Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cogni? ve de? cits in Down 
syndrome mouse models and in humans. Mol Nutr Food Res 58 (2), 278 (2014).
Deng, X. et al., The kinase Mirk/Dyrk1B mediates cell survival in pancrea? c ductal adenocarcinoma. 
Cancer Res 66 (8), 4149 (2006).
Deng, X. et al., The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G(0) by Mirk/dyrk1B kinase. 
J Biol Chem 279 (21), 22498 (2004).
Donner, A. J., Szostek, S., Hoover, J. M., and Espinosa, J. M., CDK8 is a s? mulus-speci? c posi? ve coregulator 
of p53 target genes. Mol Cell 27 (1), 121 (2007).
Even, Y. et al., CDC2L5, a Cdk-like kinase with RS domain, interacts with the ASF/SF2-associated protein 
p32 and a? ects splicing in vivo. J Cell Biochem 99 (3), 890 (2006).
Fasolo, J. et al., Diverse protein kinase interac? ons iden? ? ed by protein microarrays reveal novel 
connec? ons between cellular processes. Genes Dev 25 (7), 767 (2011).
Firestein, R. et al., CDK8 is a colorectal cancer oncogene that regulates beta-catenin ac? vity. Nature 455 
(7212), 547 (2008).
Fisher, R. P., The CDK Network: Linking Cycles of Cell Division and Gene Expression. Genes Cancer 3 (11-
12), 731 (2012).
Flanagan, P. M. et al., A mediator required for ac? va? on of RNA polymerase II transcrip? on in vitro. 
Nature 350 (6317), 436 (1991).
Fleuren, E. D., Zhang, L., Wu, J., and Daly, R. J., The kinome ‘at large’ in cancer. Nat Rev Cancer 16 (2), 83 
(2016).
Frame, S. and Cohen, P., GSK3 takes centre stage more than 20 years a? er its discovery. Biochem J 359 (Pt 
1), 1 (2001).
Friedman, E., Mirk/Dyrk1B in cancer. J Cell Biochem 102 (2), 274 (2007).
Fu, Z. et al., Iden? ? ca? on of yin-yang regulators and a phosphoryla? on consensus for male germ cell-
associated kinase (MAK)-related kinase. Mol Cell Biol 26 (22), 8639 (2006).
Fu, Z. et al., Ac? va? on of a nuclear Cdc2-related kinase within a mitogen-ac? vated protein kinase-like 
TDY mo? f by autophosphoryla? on and cyclin-dependent protein kinase-ac? va? ng kinase. Mol Cell Biol 
25 (14), 6047 (2005).
Futreal, P. A. et al., A census of human cancer genes. Nat Rev Cancer 4 (3), 177 (2004).
Ganuza, M. et al., Gene? c inac? va? on of Cdk7 leads to cell cycle arrest and induces premature aging due 
to adult stem cell exhaus? on. EMBO J 31 (11), 2498 (2012).
Gao, Q. et al., Evalua? on of cancer dependence and druggability of PRP4 kinase using cellular, 
biochemical, and structural approaches. J Biol Chem 288 (42), 30125 (2013).
Gavin, A. C. et al., Proteome survey reveals modularity of the yeast cell machinery. Nature 440 (7084), 
631 (2006).
Ghosh, G. and Adams, J. A., Phosphoryla? on mechanism and structure of serine-arginine protein kinases. 
FEBS J 278 (4), 587 (2011).
Giannakouros, T., Nikolakaki, E., Mylonis, I., and Georgatsou, E., Serine-arginine protein kinases: a small 
protein kinase family with a large cellular presence. FEBS J 278 (4), 570 (2011).
Gla? er, T., Wepf, A., Aebersold, R., and Gstaiger, M., An integrated work? ow for char? ng the human 
interac? on proteome: insights into the PP2A system. Mol Syst Biol 5, 237 (2009).
Gross, S. et al., Targe? ng cancer with kinase inhibitors. J Clin Invest 125 (5), 1780 (2015).
Guen, V. J. et al., CDK10/cyclin M is a protein kinase that controls ETS2 degrada? on and is de? cient in 
STAR syndrome. Proc Natl Acad Sci U S A 110 (48), 19525 (2013).
Guo, X., Williams, J. G., Schug, T. T., and Li, X., DYRK1A and DYRK3 promote cell survival through 
phosphoryla? on and ac? va? on of SIRT1. J Biol Chem 285 (17), 13223 (2010).
Harper, J. and Brooks, G., The Mammalian Cell Cycle - An Overwiew. From Methods in Molecular Biology, 
vol 296, Cell Cycle Control: Mechanisms and Protocols. Edited by: T. Humphrey and G. Brooks. (Humana 
Press Inc., Totowa, NJ, 2005).
Has? e, C. J., McLauchlan, H. J., and Cohen, P., Assay of protein kinases using radiolabeled ATP: a protocol. 
Nat Protoc 1 (2), 968 (2006).
Hayes, G. M., Carrigan, P. E., and Miller, L. J., Serine-arginine protein kinase 1 overexpression is associated 
with tumorigenic imbalance in mitogen-ac? vated protein kinase pathways in breast, colonic, and 
pancrea? c carcinomas. Cancer Res 67 (5), 2072 (2007).
References
42
Heikkinen, T. et al., Soma? c MED12 Nonsense Muta? on Escapes mRNA Decay and Reveals a Mo? f 
Required for Nuclear Entry. Hum Mutat 38 (3), 269 (2017).
Himpel, S. et al., Iden? ? ca? on of the autophosphoryla? on sites and characteriza? on of their e? ects in 
the protein kinase DYRK1A. Biochem J 359 (Pt 3), 497 (2001).
Hishizawa, M. et al., Serological iden? ? ca? on of adult T-cell leukaemia-associated an? gens. Br J Haematol 
130 (3), 382 (2005).
Hoe? ich, K. P. et al., Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB 
ac? va? on. Nature 406 (6791), 86 (2000).
Hu, J., Deng, H., and Friedman, E. A., Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B 
kinase inhibi? on. Int J Cancer 132 (10), 2258 (2013).
Iorns, E. et al., Iden? ? ca? on of CDK10 as an important determinant of resistance to endocrine therapy 
for breast cancer. Cancer Cell 13 (2), 91 (2008).
Jang, S. W. et al., Serine/arginine protein-speci? c kinase 2 promotes leukemia cell prolifera? on by 
phosphoryla? ng acinus and regula? ng cyclin A1. Cancer Res 68 (12), 4559 (2008).
Je? rey, P. D. et al., Mechanism of CDK ac? va? on revealed by the structure of a cyclinA-CDK2 complex. 
Nature 376 (6538), 313 (1995).
Jiang, M. et al., Cyclin Y, a novel membrane-associated cyclin, interacts with PFTK1. FEBS Le?  583 (13), 
2171 (2009).
Jin, F., Claessens, F., and Fondell, J. D., Regula? on of androgen receptor-dependent transcrip? on by 
coac? vator MED1 is mediated through a newly discovered noncanonical binding mo? f. J Biol Chem 287 
(2), 858 (2012).
Jin, F. et al., ERK and AKT signaling drive MED1 overexpression in prostate cancer in associa? on with 
elevated prolifera? on and tumorigenicity. Mol Cancer Res 11 (7), 736 (2013).
Johnson, G. L. and Lapadat, R., Mitogen-ac? vated protein kinase pathways mediated by ERK, JNK, and 
p38 protein kinases. Science 298 (5600), 1911 (2002).
Johnson, L. N., Noble, M. E., and Owen, D. J., Ac? ve and inac? ve protein kinases: structural basis for 
regula? on. Cell 85 (2), 149 (1996).
Joshi, P. M., Sutor, S. L., Huntoon, C. J., and Karnitz, L. M., Ovarian cancer-associated muta? ons disable 
cataly? c ac? vity of CDK12, a kinase that promotes homologous recombina? on repair and resistance to 
cispla? n and poly(ADP-ribose) polymerase inhibitors. J Biol Chem 289 (13), 9247 (2014).
Juan, H. C., Lin, Y., Chen, H. R., and Fann, M. J., Cdk12 is essen? al for embryonic development and the 
maintenance of genomic stability. Cell Death Di? er 23 (6), 1038 (2016).
Kaidanovich-Beilin, O. and Woodge? , J. R., GSK-3: Func? onal Insights from Cell Biology and Animal 
Models. Front Mol Neurosci 4, 40 (2011).
Kampjarvi, K. et al., Soma? c MED12 muta? ons are associated with poor prognosis markers in chronic 
lymphocy? c leukemia. Oncotarget 6 (3), 1884 (2015).
Kampjarvi, K. et al., Soma? c MED12 muta? ons in prostate cancer and uterine leiomyomas promote 
tumorigenesis through dis? nct mechanisms. Prostate 76 (1), 22 (2016).
Kannan, N. and Neuwald, A. F., Evolu? onary constraints associated with func? onal speci? city of the 
CMGC protein kinases MAPK, CDK, GSK, SRPK, DYRK, and CK2alpha. Protein Sci 13 (8), 2059 (2004).
Kauraniemi, P., Barlund, M., Monni, O., and Kallioniemi, A., New ampli? ed and highly expressed genes 
discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res 61 (22), 8235 
(2001).
Kauraniemi, P., Kuukasjarvi, T., Sauter, G., and Kallioniemi, A., Ampli? ca? on of a 280-kilobase core region 
at the ERBB2 locus leads to ac? va? on of two hypothe? cal proteins in breast cancer. Am J Pathol 163 
(5), 1979 (2003).
Kelleher, R. J., 3rd, Flanagan, P. M., and Kornberg, R. D., A novel mediator between ac? vator proteins and 
the RNA polymerase II transcrip? on apparatus. Cell 61 (7), 1209 (1990).
Kerppola, T. K., Design and implementa? on of bimolecular ? uorescence complementa? on (BiFC) assays 
for the visualiza? on of protein interac? ons in living cells. Nat Protoc 1 (3), 1278 (2006).
Kim, D. I. et al., Probing nuclear pore complex architecture with proximity-dependent bio? nyla? on. Proc 
Natl Acad Sci U S A 111 (24), E2453 (2014).
Kim, S., Xu, X., Hecht, A., and Boyer, T. G., Mediator is a transducer of Wnt/beta-catenin signaling. J Biol 
Chem 281 (20), 14066 (2006).
Knight, Z. A., Lin, H., and Shokat, K. M., Targe? ng the cancer kinome through polypharmacology. Nat Rev 
Cancer 10 (2), 130 (2010).
References
43
Knuesel, M. T., Meyer, K. D., Bernecky, C., and Taatjes, D. J., The human CDK8 subcomplex is a molecular 
switch that controls Mediator coac? vator func? on. Genes Dev 23 (4), 439 (2009a).
Knuesel, M. T. et al., The human CDK8 subcomplex is a histone kinase that requires Med12 for ac? vity 
and can func? on independently of mediator. Mol Cell Biol 29 (3), 650 (2009b).
Kojima, T. et al., Cloning of human PRP4 reveals interac? on with Clk1. J Biol Chem 276 (34), 32247 
(2001).
Kontro, M. et al., Novel ac? va? ng STAT5B muta? ons as puta? ve drivers of T-cell acute lymphoblas? c 
leukemia. Leukemia 28 (8), 1738 (2014).
Kramer, T., Schmidt, B., and Lo Monte, F., Small-Molecule Inhibitors of GSK-3: Structural Insights and 
Their Applica? on to Alzheimer’s Disease Models. Int J Alzheimers Dis 2012, 381029 (2011).
Krogan, N. J. et al., Global landscape of protein complexes in the yeast Saccharomyces cerevisiae. Nature 
440 (7084), 637 (2006).
Lahiry, P. et al., A mul? plex human syndrome implicates a key role for intes? nal cell kinase in 
development of central nervous, skeletal, and endocrine systems. Am J Hum Genet 84 (2), 134 (2009).
Li, T., Inoue, A., Lah? , J. M., and Kidd, V. J., Failure to proliferate and mito? c arrest of CDK11(p110/p58)-
null mutant mice at the blastocyst stage of embryonic cell development. Mol Cell Biol 24 (8), 3188 
(2004).
Lin, C., Franco, B., and Rosner, M. R., CDKL5/Stk9 kinase inac? va? on is associated with neuronal 
developmental disorders. Hum Mol Genet 14 (24), 3775 (2005).
Liu, C. et al., Cyclin I-like (CCNI2) is a cyclin-dependent kinase 5 (CDK5) ac? vator and is involved in cell 
cycle regula? on. Sci Rep 7, 40979 (2017).
Liu, W. et al., Cdk5 links with DNA damage response and cancer. Mol Cancer 16 (1), 60 (2017).
Lochhead, P. A., Sibbet, G., Morrice, N., and Cleghon, V., Ac? va? on-loop autophosphoryla? on is 
mediated by a novel transi? onal intermediate form of DYRKs. Cell 121 (6), 925 (2005).
Loyer, P. et al., Characteriza? on of cyclin L1 and L2 interac? ons with CDK11 and splicing factors: in? uence 
of cyclin L isoforms on splice site selec? on. J Biol Chem 283 (12), 7721 (2008).
MacAulay, K. et al., Glycogen synthase kinase 3alpha-speci? c regula? on of murine hepa? c glycogen 
metabolism. Cell Metab 6 (4), 329 (2007).
Makinen, N. et al., Muta? on analysis of components of the Mediator kinase module in MED12 muta? on-
nega? ve uterine leiomyomas. Br J Cancer 110 (9), 2246 (2014).
Makinen, N. et al., MED12, the mediator complex subunit 12 gene, is mutated at high frequency in 
uterine leiomyomas. Science 334 (6053), 252 (2011).
Malumbres, M., Cyclin-dependent kinases. Genome Biol 15 (6), 122 (2014).
Malumbres, M. and Barbacid, M., Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9 
(3), 153 (2009).
Malumbres, M. et al., Cyclin-dependent kinases: a family portrait. Nat Cell Biol 11 (11), 1275 (2009).
Malumbres, M. et al., Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and 
Cdk6. Cell 118 (4), 493 (2004).
Mann, M. et al., Analysis of protein phosphoryla? on using mass spectrometry: deciphering the 
phosphoproteome. Trends Biotechnol 20 (6), 261 (2002).
Manning, G. et al., The protein kinase complement of the human genome. Science 298 (5600), 1912 
(2002).
Mari, F. et al., CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the 
early-onset seizure variant of Re?  syndrome. Hum Mol Genet 14 (14), 1935 (2005).
McCubrey, J. A. et al., E? ects of muta? ons in Wnt/beta-catenin, hedgehog, Notch and PI3K pathways on 
GSK-3 ac? vity-Diverse e? ects on cell growth, metabolism and cancer. Biochim Biophys Acta 1863 (12), 
2942 (2016).
Medina, M. and Wandosell, F., Deconstruc? ng GSK-3: The Fine Regula? on of Its Ac? vity. Int J Alzheimers 
Dis 2011, 479249 (2011).
Mehta, P. B. et al., MEK5 overexpression is associated with metasta? c prostate cancer, and s? mulates 
prolifera? on, MMP-9 expression and invasion. Oncogene 22 (9), 1381 (2003).
Mellacheruvu, D. et al., The CRAPome: a contaminant repository for a?  nity puri? ca? on-mass 
spectrometry data. Nat Methods 10 (8), 730 (2013).
Meng, L. et al., Protein kinase substrate iden? ? ca? on on func? onal protein arrays. BMC Biotechnol 8, 
22 (2008).
References
44
Mercer, S. E. et al., Mirk/Dyrk1b mediates cell survival in rhabdomyosarcomas. Cancer Res 66 (10), 5143 
(2006).
Miyata, Y., Akashi, M., and Nishida, E., Molecular cloning and characteriza? on of a novel member of the 
MAP kinase superfamily. Genes Cells 4 (5), 299 (1999).
Mok, J., Im, H., and Snyder, M., Global iden? ? ca? on of protein kinase substrates by protein microarray 
analysis. Nat Protoc 4 (12), 1820 (2009).
Montembault, E., Dutertre, S., Prigent, C., and Giet, R., PRP4 is a spindle assembly checkpoint protein 
required for MPS1, MAD1, and MAD2 localiza? on to the kinetochores. J Cell Biol 179 (4), 601 (2007).
Moon, H. et al., Intes? nal cell kinase, a protein associated with endocrine-cerebro-osteodysplasia 
syndrome, is a key regulator of cilia length and Hedgehog signaling. Proc Natl Acad Sci U S A 111 (23), 
8541 (2014).
Morris, E. J. et al., E2F1 represses beta-catenin transcrip? on and is antagonized by both pRB and CDK8. 
Nature 455 (7212), 552 (2008).
Mulloy, R., Salinas, S., Philips, A., and Hipskind, R. A., Ac? va? on of cyclin D1 expression by the ERK5 
cascade. Oncogene 22 (35), 5387 (2003).
Murphy, L. O. et al., Molecular interpreta? on of ERK signal dura? on by immediate early gene products. 
Nat Cell Biol 4 (8), 556 (2002).
Nayler, O., Stamm, S., and Ullrich, A., Characteriza? on and comparison of four serine- and arginine-rich 
(SR) protein kinases. Biochem J 326 ( Pt 3), 693 (1997).
Niehrs, C., The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol 13 (12), 767 (2012).
Nolen, B., Taylor, S., and Ghosh, G., Regula? on of protein kinases; controlling ac? vity through ac? va? on 
segment conforma? on. Mol Cell 15 (5), 661 (2004).
Ohshima, T. et al., Targeted disrup? on of the cyclin-dependent kinase 5 gene results in abnormal 
cor? cogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci U S A 93 (20), 11173 (1996).
Omori, Y. et al., Nega? ve regula? on of ciliary length by ciliary male germ cell-associated kinase (Mak) is 
required for re? nal photoreceptor survival. Proc Natl Acad Sci U S A 107 (52), 22671 (2010).
Ordulu, Z., Fibroids: Genotype and Phenotype. Clin Obstet Gynecol 59 (1), 25 (2016).
Ortega, S. et al., Cyclin-dependent kinase 2 is essen? al for meiosis but not for mito? c cell division in mice. 
Nat Genet 35 (1), 25 (2003).
Oruganty, K. and Kannan, N., Design principles underpinning the regulatory diversity of protein kinases. 
Philos Trans R Soc Lond B Biol Sci 367 (1602), 2529 (2012).
Ozgul, R. K. et al., Exome sequencing and cis-regulatory mapping iden? fy muta? ons in MAK, a gene 
encoding a regulator of ciliary length, as a cause of re? ni? s pigmentosa. Am J Hum Genet 89 (2), 253 
(2011).
Pandey, M. K. and DeGrado, T. R., Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging. 
Theranos? cs 6 (4), 571 (2016).
Park, J., Song, W. J., and Chung, K. C., Func? on and regula? on of Dyrk1A: towards understanding Down 
syndrome. Cell Mol Life Sci 66 (20), 3235 (2009).
Park, M. H., Kim, S. Y., Kim, Y. J., and Chung, Y. H., ALS2CR7 (CDK15) a? enuates TRAIL induced apoptosis 
by inducing phosphoryla? on of survivin Thr34. Biochem Biophys Res Commun 450 (1), 129 (2014).
Patel, H. et al., Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognos? c in 
Estrogen Receptor-Posi? ve Breast Cancer. Clin Cancer Res 22 (23), 5929 (2016).
Pawson, T. and Nash, P., Assembly of cell regulatory systems through protein interac? on domains. Science 
300 (5618), 445 (2003).
Petsalaki, E. and Zachos, G., Clks 1, 2 and 4 prevent chroma? n breakage by regula? ng the Aurora 
B-dependent abscission checkpoint. Nat Commun 7, 11451 (2016).
Prasad, J., Colwill, K., Pawson, T., and Manley, J. L., The protein kinase Clk/Sty directly modulates SR 
protein ac? vity: both hyper- and hypophosphoryla? on inhibit splicing. Mol Cell Biol 19 (10), 6991 
(1999).
Rane, S. G. et al., Loss of Cdk4 expression causes insulin-de? cient diabetes and Cdk4 ac? va? on results in 
beta-islet cell hyperplasia. Nat Genet 22 (1), 44 (1999).
Regan, C. P. et al., Erk5 null mice display mul? ple extraembryonic vascular and embryonic cardiovascular 
defects. Proc Natl Acad Sci U S A 99 (14), 9248 (2002).
Ren, S. and Rollins, B. J., Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell 117 (2), 239 (2004).
Roux, K. J., Kim, D. I., Raida, M., and Burke, B., A promiscuous bio? n ligase fusion protein iden? ? es 
proximal and interac? ng proteins in mammalian cells. J Cell Biol 196 (6), 801 (2012).
References
45
Rual, J. F. et al., Human ORFeome version 1.1: a pla? orm for reverse proteomics. Genome Res 14 (10B), 
2128 (2004).
Rual, J. F. et al., Towards a proteome-scale map of the human protein-protein interac? on network. Nature 
437 (7062), 1173 (2005).
Russo, A. A., Je? rey, P. D., and Pavle? ch, N. P., Structural basis of cyclin-dependent kinase ac? va? on by 
phosphoryla? on. Nat Struct Biol 3 (8), 696 (1996).
Santamaria, D. et al., Cdk1 is su?  cient to drive the mammalian cell cycle. Nature 448 (7155), 811 (2007).
Seifert, A., Allan, L. A., and Clarke, P. R., DYRK1A phosphorylates caspase 9 at an inhibitory site and is 
potently inhibited in human cells by harmine. FEBS J 275 (24), 6268 (2008).
Shah, K. and Lahiri, D. K., Cdk5 ac? vity in the brain - mul? ple paths of regula? on. J Cell Sci 127 (Pt 11), 
2391 (2014).
Shaikhibrahim, Z. et al., MED15, encoding a subunit of the mediator complex, is overexpressed at high 
frequency in castra? on-resistant prostate cancer. Int J Cancer 135 (1), 19 (2014a).
Shaikhibrahim, Z. et al., MED12 overexpression is a frequent event in castra? on-resistant prostate cancer. 
Endocr Relat Cancer 21 (4), 663 (2014b).
Shehata, S. N. et al., Analysis of substrate speci? city and cyclin Y binding of PCTAIRE-1 kinase. Cell Signal 
24 (11), 2085 (2012).
Shimizu, N. et al., Hipk2 and PP1c cooperate to maintain Dvl protein levels required for Wnt signal 
transduc? on. Cell Rep 8 (5), 1391 (2014).
Taira, N. et al., DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphoryla? on in the 
apopto? c response to DNA damage. Mol Cell 25 (5), 725 (2007).
Tao, J. et al., Muta? ons in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated 
with severe neurodevelopmental retarda? on. Am J Hum Genet 75 (6), 1149 (2004).
Taylor, S. S. and Kornev, A. P., Protein kinases: evolu? on of dynamic regulatory proteins. Trends Biochem 
Sci 36 (2), 65 (2011).
ter Haar, E. et al., Structure of GSK3beta reveals a primed phosphoryla? on mechanism. Nat Struct Biol 8 
(7), 593 (2001).
Treiber, D. K. and Shah, N. P., Ins and outs of kinase DFG mo? fs. Chem Biol 20 (6), 745 (2013).
Tsai, K. L. et al., A conserved Mediator-CDK8 kinase module associa? on regulates Mediator-RNA 
polymerase II interac? on. Nat Struct Mol Biol 20 (5), 611 (2013).
Tsai, K. L. et al., Subunit architecture and func? onal modular rearrangements of the transcrip? onal 
mediator complex. Cell 157 (6), 1430 (2014).
Tsutsui, T. et al., Targeted disrup? on of CDK4 delays cell cycle entry with enhanced p27(Kip1) ac? vity. Mol 
Cell Biol 19 (10), 7011 (1999).
Tucker, B. A. et al., Exome sequencing and analysis of induced pluripotent stem cells iden? fy the cilia-
related gene male germ cell-associated kinase (MAK) as a cause of re? ni? s pigmentosa. Proc Natl Acad 
Sci U S A 108 (34), E569 (2011).
Turunen, M. et al., Uterine leiomyoma-linked MED12 muta? ons disrupt mediator-associated CDK ac? vity. 
Cell Rep 7 (3), 654 (2014).
Uetz, P. et al., A comprehensive analysis of protein-protein interac? ons in Saccharomyces cerevisiae. 
Nature 403 (6770), 623 (2000).
Van den Veyver, I. B. and Zoghbi, H. Y., Muta? ons in the gene encoding methyl-CpG-binding protein 2 
cause Re?  syndrome. Brain Dev 23 Suppl 1, S147 (2001).
van der Laden, J., Soppa, U., and Becker, W., E? ect of tyrosine autophosphoryla? on on cataly? c ac? vity 
and subcellular localisa? on of homeodomain-interac? ng protein kinases (HIPK). Cell Commun Signal 
13, 3 (2015).
Varjosalo, M. et al., Applica? on of ac? ve and kinase-de? cient kinome collec? on for iden? ? ca? on of 
kinases regula? ng hedgehog signaling. Cell 133 (3), 537 (2008).
Varjosalo, M. et al., Interlaboratory reproducibility of large-scale human protein-complex analysis by 
standardized AP-MS. Nat Methods 10 (4), 307 (2013a).
Varjosalo, M. et al., The protein interac? on landscape of the human CMGC kinase group. Cell Rep 3 (4), 
1306 (2013b).
Varnaite, R. and MacNeill, S. A., Meet the neighbors: Mapping local protein interactomes by proximity-
dependent labeling with BioID. Proteomics 16 (19), 2503 (2016).
Vijayvargia, R., May, M. S., and Fondell, J. D., A coregulatory role for the mediator complex in prostate 
cancer cell prolifera? on and gene expression. Cancer Res 67 (9), 4034 (2007).
References
46
Vojnic, E. et al., Structure and VP16 binding of the Mediator Med25 ac? vator interac? on domain. Nat 
Struct Mol Biol 18 (4), 404 (2011).
Wang, L. Y. and Kung, H. J., Male germ cell-associated kinase is overexpressed in prostate cancer cells and 
causes mito? c defects via deregula? on of APC/CCDH1. Oncogene 31 (24), 2907 (2011).
Weaving, L. S. et al., Muta? ons of CDKL5 cause a severe neurodevelopmental disorder with infan? le 
spasms and mental retarda? on. Am J Hum Genet 75 (6), 1079 (2004).
Westerling, T., Kuuluvainen, E., and Makela, T. P., Cdk8 is essen? al for preimplanta? on mouse 
development. Mol Cell Biol 27 (17), 6177 (2007).
Woodge? , J. R., Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9 (8), 
2431 (1990).
Yang, C. et al., The kinase Mirk is a poten? al therapeu? c target in osteosarcoma. Carcinogenesis 31 (4), 
552 (2010).
Yang, Y., Roine, N., and Makela, T. P., CCRK deple? on inhibits glioblastoma cell prolifera? on in a cilium-
dependent manner. EMBO Rep 14 (8), 741 (2013).
Yin, J. W. and Wang, G., The Mediator complex: a master coordinator of transcrip? on and cell lineage 
development. Development 141 (5), 977 (2014).
Zhou, H., Kim, S., Ishii, S., and Boyer, T. G., Mediator modulates Gli3-dependent Sonic hedgehog signaling. 
Mol Cell Biol 26 (23), 8667 (2006).
Zhou, R. et al., SOX9 interacts with a component of the human thyroid hormone receptor-associated 
protein complex. Nucleic Acids Res 30 (14), 3245 (2002).
Zhu, H. et al., Global analysis of protein ac? vi? es using proteome chips. Science 293 (5537), 2101 (2001).
Zou, Y. et al., Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphoryla? on at threonine 288. J Biol Chem 
279 (26), 27790 (2004).
References
CMGC Kinases and Cancer
SALLA KESKITALO
dissertationes scholae doctoralis ad sanitatem investigandam 
universitatis helsinkiensis 37/2017
37/2017
Helsinki 2017                       ISSN 2342-3161                 ISBN 978-951-51-3503-2 
SA
LL
A
 K
E
SK
ITA
L
O
    C
M
G
C
 K
in
ases an
d C
an
cer
Recent Publications in this Series
16/2017 Irene Ylivinkka
Netrins in Glioma Biology: Regulators of Tumor Cell Proliferation, Motility and Stemness
17/2017 Elisa Lázaro Ibáñez
Extracellular Vesicles: Prospects in Prostate Cancer Biomarker Discovery and Drug Delivery 
18/2017 Anu Kaskinen
Measurement of Lung Liquid and Outcome after Congenital Cardiac Surgery
19/2017 Taru Hilander
Molecular Consequences of Transfer-RNA Charging Defects
20/2017 Laura Teirilä
Activation of the Inflammatory Response by Fungal Components
21/2017 Laura Sokka
Burnout in the Brain at Work
22/2018 Martti Rechardt
Metabolic and Inflammatory Factors in Upper Extremity Soft-Tissue Disorders
23/2017 Jaana Hautala
Improving the Palatability of Minitablets for Feline Medication
24/2017 Satu Lehti
Extracellular Lipid Particles in Atherosclerosis and Aortic Stenosis
25/2017 Asko Wegelius
Influence of Birth Weight on the Risk and Clinical Presentation of Schizophrenia
26/2017 Siva Prasada Reddy Maddirala Venkata
Public Health and Patient Care Aspects in Pharmacy Education and Pharmacists’ Role in 
National Public Health Programs in India
27/2017 Kristyna Spillerova
The Role of the Angiosome Concept in the Treatment of below the knee Critical Limb Ischemia
28/2017 Anna-Riia Holmström
Learning from Medication Errors in Healthcare  — How to Make Medication Error Reporting 
Systems Work?
29/2017 Aaro Haapaniemi
Laryngeal Cancer Recurrence, Prognostic Factors and Management
30/2017 Reeta Talka
Effects of Opioids on Neuronal Nicotinic Acetylcholine Receptors
31/2017 Andreas Helfenstein
Fighting Bugs by Numbers: Bioinformatics Tools for Antimicrobial Drug Discovery
32/2017 Feven Tigistu-Sahle
Metabolism of Polyunsaturated Fatty Acids in Human Bone Marrow Derived Mesenchymal 
Stromal Cells
33/2017 Maija Miettinen
Vitamin D and Type 1 Diabetes
34/2017 Antti-Pekka Rissanen
Oxygen Delivery and Utilization during Acute Dynamic Exercise: Effects of 
Polycystic Ovary Syndrome, Type 1 Diabetes, and Exercise Training
35/2017 Harri Nurmi
Role of the VEGFC/VEGFR3 Pathway, Beyond Developmental 
Lymphangiogenesis
36/2017 Mohamed Mostafa Mohamed Ahmed El Missiry
Early Treatment Prediction and Immunological Effects of Tyrosine Kinase 
Inhibitor Therapy in Chronic-Phase Chronic Myeloid Leukemia
INSTITUTE OF BIOTECHNOLOGY AND
DEPARTMENT OF BIOSCIENCES
FACULTY OF BIOLOGICAL AND ENVIRONMENTAL SCIENCES
DOCTORAL PROGRAMME IN INTEGRATIVE LIFE SCIENCE 
UNIVERSITY OF HELSINKI
  
